Domain > www.targetedonc.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2019-03-15	54.84.196.35 (ClassC)
2025-08-04	76.76.21.98 (ClassC)

HTTP/1.1 200 OKAge: 838Cache-Control: public, max-age0, must-revalidateContent-Length: 470465Content-Type: text/html; charsetutf-8Date: Mon, 04 Aug 2025 10:56:52 GMTEtag: y8zm3g4isda2yeServer: VercelStrict-Transport-Security: max-age63072000X-Matched-Path: /X-Powered-By: Next.jsX-Vercel-Cache: HITX-Vercel-Id: pdx1::cle1::4sm8m-1754305850675-64d41974ef4c

!DOCTYPE html>html langen>head>meta charSetutf-8/>meta nameviewport contentwidthdevice-width/>script srchttps://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js>/script>title>Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways/title>meta namedescription contentTargeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies./>meta propertyog:url contenthttps://www.targetedonc.com  />meta propertyog:title contentTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways/>meta propertyog:image contenthttps://s3.amazonaws.com/mjhlifesciences.com/sitelogos/TargetedOnc_1200x637.png/>meta propertyog:site_name contentTargeted Oncology/>meta propertyog:description contentTargeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies./>meta nametwitter:card contentsummary/>meta nametwitter:title contentTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways/>meta nametwitter:image contenthttps://s3.amazonaws.com/mjhlifesciences.com/sitelogos/TargetedOnc_1200x637.png/>meta nametwitter:site content@@TargetedOnc/>meta nametwitter:description contentTargeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies./>meta namerobots contentmax-image-preview:large/>meta namerobots contentmax-video-preview:-1/>link relpreconnect dns-prefetch hrefhttps://cmp.osano.com/>link relpreconnect dns-prefetch hrefhttps://res.lassomarketing.io/>link relpreconnect dns-prefetch hrefhttps://www.lightboxcdn.com/>link relpreconnect dns-prefetch hrefhttps://pub.doubleverify.com/>link relpreconnect dns-prefetch hrefhttps://cdn.doubleverify.com/>link relpreconnect dns-prefetch hrefhttps://cdn.segment.com/>link relpreconnect dns-prefetch hrefhttps://securepubads.g.doubleclick.net/>link relpreconnect dns-prefetch hrefhttps://pagead2.googlesyndication.com/>link relpreconnect dns-prefetch hrefhttps://cdn.sanity.io/>link relpreconnect dns-prefetch hrefhttps://www.google-analytics.com/>link relpreconnect dns-prefetch hrefhttps://www.googletagmanager.com/>link relpreconnect dns-prefetch hrefhttps://player.vimeo.com/>link relpreconnect dns-prefetch hrefhttps://youtube.com/>link relpreconnect dns-prefetch hrefhttps://connect.facebook.net/>link relpreconnect dns-prefetch hrefhttps://www.facebook.com/>link relpreconnect dns-prefetch hrefhttps://static.ads-twitter.com/>link relpreconnect dns-prefetch hrefhttps://ad.doubleclick.net/>link relpreload asscript hrefhttps://securepubads.g.doubleclick.net/tag/js/gpt.js/>link relicon href/favicon.ico/>script typetext/javascript async srchttps://securepubads.g.doubleclick.net/tag/js/gpt.js>/script>script async srchttps://pub.doubleverify.com/dvtag/20083417/DV1815449/pub.js>/script>script typemodule>            window.onDvtagReady  function (callback, timeout  750) {             window.dvtag  window.dvtag || {}             dvtag.cmd  dvtag.cmd ||              const opt  { callback, timeout, timestamp: new Date().getTime() }             dvtag.cmd.push(function () { dvtag.queueAdRequest(opt) })             setTimeout(function () {             const cb  opt.callback             opt.callback  null             if (cb) cb()             }, timeout)             }             /script>meta namekeywords contentcancer,oncology/>script srchttps://one.targetedonc.com/tagmanager/scripts/one.js>/script>script>window.dataLayer  window.dataLayer || ;            setTimeout(() > {        window.dataLayer.push({            event: page_dimensions,            pageTitle: Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways,            dimension9: home,            dimension11: ,            dimension12: ,            dimension13: ,            dimension14: ,            dimension15: home,            dimension18: ,            dimension19: ,            dimension20: ,          });            },500)         /script>script typetext/javascript>          (function(w,d,s,l,i){wlwl||;wl.push({gtm.start:          new Date().getTime(),event:gtm.js});var fd.getElementsByTagName(s)0,          jd.createElement(s),dll!dataLayer?&l+l:;j.asynctrue;j.src          https://www.googletagmanager.com/gtm.js?id+i+dl;f.parentNode.insertBefore(j,f);          })(window,document,script,dataLayer,GTM-KKCZB52);          /script>script typemodule>          var ALGOLIA_INSIGHTS_SRC  https://cdn.jsdelivr.net/npm/search-insights@2.4.0;          !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObjects,eses||function(){          (es.queuees.queue||).push(arguments)},ia.createElement(t),ca.getElementsByTagName(t)0,          i.async1,i.srcn,c.parentNode.insertBefore(i,c)          }(window,document,script,ALGOLIA_INSIGHTS_SRC,aa);/script>link relcanonical hrefhttps://www.targetedonc.com/>script typeapplication/ld+json>{@context:https://schema.org,@type:Organization,logo:https://www.targetedonc.com/TargetedOnc_logo.png,url:https://www.targetedonc.com,contactPoint:{@type:ContactPoint,availableLanguage:English},name:Targeted Healthcare Communications,alternateName:TargetedOnc,description:Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.,sameAs:https://www.facebook.com/TargetedOnc/,https://www.linkedin.com/company/targetedonc,https://twitter.com/TargetedOnc,https://www.youtube.com/user/TargetedHC,https://www.instagram.com/targetedoncology/,address:{@type:PostalAddress,streetAddress:2 Commerce Drive,addressLocality:Cranbury,addressRegion:New Jersey,postalCode:08512,addressCountry:United States of America},foundingDate:2013-09-07,founder:{@type:Person,name:MJH Life Sciences},employees:{@type:Person,name:Silas Inman},{@type:Person,name:Kristie Kahl},{@type:Person,name:Dylann Cohn-Emery}}/script>meta namenext-head-count content12/>link relpreconnect hrefhttps://res.lassomarketing.io/>script async typetext/javascript srchttps://www.lightboxcdn.com/static/lightbox_mjh.js>/script>script defer srchttps://res.lassomarketing.io/scripts/lasso-imp-id-min.js typetext/javascript>/script> script defer typetext/javascript srchttps://www.googletagservices.com/tag/js/gpt.js>/script> script typemodule>            !function(){var analyticswindow.analyticswindow.analytics||;if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error(Segment snippet included twice.);else{analytics.invoked!0;analytics.methodstrackSubmit,trackClick,trackLink,trackForm,pageview,identify,reset,group,track,ready,alias,debug,page,once,off,on,addSourceMiddleware,addIntegrationMiddleware,setAnonymousId,addDestinationMiddleware;analytics.factoryfunction(e){return function(){var tArray.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e0;eanalytics.methods.length;e++){var keyanalytics.methodse;analyticskeyanalytics.factory(key)}analytics.loadfunction(key,e){var tdocument.createElement(script);t.typetext/javascript;t.async!0;t.srchttps://cdn.segment.com/analytics.js/v1/ + key + /analytics.min.js;var ndocument.getElementsByTagName(script)0;n.parentNode.insertBefore(t,n);analytics._loadOptionse};analytics.SNIPPET_VERSION4.13.1;              window.LassoImpressionID  lassoImpID();              analytics.load(BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN);              analytics.page({              LassoImpressionID: window.LassoImpressionID              });            }}(); /script>  script srchttps://www.googleoptimize.com/optimize.js?idOPT-NVFJRDN>/script>link relpreload href/_next/static/css/6579996ef7ee61dd.css asstyle/>link relstylesheet href/_next/static/css/6579996ef7ee61dd.css data-n-g/>link relpreload href/_next/static/css/159521ba7be98a3c.css asstyle/>link relstylesheet href/_next/static/css/159521ba7be98a3c.css data-n-p/>noscript data-n-css>/noscript>script defer nomodule src/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js>/script>script src/_next/static/chunks/webpack-d6c50a66a9d7a23b.js defer>/script>script src/_next/static/chunks/framework-45ce3d09104a2cae.js defer>/script>script src/_next/static/chunks/main-c1ce322a402d266c.js defer>/script>script src/_next/static/chunks/pages/_app-f08303ef8d52242f.js defer>/script>script src/_next/static/chunks/72585f70-3f08d4290ca968de.js defer>/script>script src/_next/static/chunks/065a3ddb-725c81816933c5e2.js defer>/script>script src/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js defer>/script>script src/_next/static/chunks/f36c6662-e730e1316f9aa347.js defer>/script>script src/_next/static/chunks/8eec4907-3e083fdcb8f62d72.js defer>/script>script src/_next/static/chunks/9814d858-cb162ab048445baf.js defer>/script>script src/_next/static/chunks/59b4e022-12a1c6f09c31aa87.js defer>/script>script src/_next/static/chunks/6536-a5087444637b0134.js defer>/script>script src/_next/static/chunks/9871-fbf0f0509af096a7.js defer>/script>script src/_next/static/chunks/4179-91956f2d2c4bf724.js defer>/script>script src/_next/static/chunks/6650-0870acf12173b5a4.js defer>/script>script src/_next/static/chunks/3270-b42873a18b956c52.js defer>/script>script src/_next/static/chunks/7707-5f57752353146674.js defer>/script>script src/_next/static/chunks/475-727a79a85a958c3e.js defer>/script>script src/_next/static/chunks/5007-396c9479c260b6fb.js defer>/script>script src/_next/static/chunks/pages/index-91692fe779fa8acf.js defer>/script>script src/_next/static/zQw7jHyvd9hhvqSVfZfeG/_buildManifest.js defer>/script>script src/_next/static/zQw7jHyvd9hhvqSVfZfeG/_ssgManifest.js defer>/script>style id__jsx-1661e6713d4eb9b5>.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 divid*google_ads_iframe.jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}/style>style id__jsx-19ede9f0a5a45918>.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}/style>style id__jsx-1588017350>.button.jsx-1588017350{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-1588017350::before{content:In-Person Event;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-1588017350{height:0px}.pill.jsx-1588017350::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-1588017350{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1588017350::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1588017350::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1588017350{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1588017350{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1588017350{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0undefined.jsx-1588017350:hover{background:var(--secondary)}.view-more-wrap0undefined.jsx-1588017350{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0undefined.jsx-1588017350:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1588017350{background-position:right bottom}.text-white.jsx-1588017350{color:var(--primary)}/style>style id__jsx-4267007461>.button.jsx-4267007461{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-4267007461::before{content:Video;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-4267007461{height:0px}.pill.jsx-4267007461::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-4267007461{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-4267007461::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-4267007461::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-4267007461{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-4267007461{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-4267007461{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore1undefined.jsx-4267007461:hover{background:var(--secondary)}.view-more-wrap1undefined.jsx-4267007461{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap1undefined.jsx-4267007461:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-4267007461{background-position:right bottom}.text-white.jsx-4267007461{color:var(--primary)}/style>style id__jsx-1229105766>.button.jsx-1229105766{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-1229105766::before{content:Video;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-1229105766{height:0px}.pill.jsx-1229105766::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-1229105766{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1229105766::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1229105766::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1229105766{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1229105766{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1229105766{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2undefined.jsx-1229105766:hover{background:var(--secondary)}.view-more-wrap2undefined.jsx-1229105766{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2undefined.jsx-1229105766:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1229105766{background-position:right bottom}.text-white.jsx-1229105766{color:var(--primary)}/style>style id__jsx-156758459>.button.jsx-156758459{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-156758459::before{content:Multimedia;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-156758459{height:0px}.pill.jsx-156758459::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-156758459{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-156758459::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-156758459::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-156758459{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-156758459{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-156758459{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore3undefined.jsx-156758459:hover{background:var(--secondary)}.view-more-wrap3undefined.jsx-156758459{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap3undefined.jsx-156758459:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-156758459{background-position:right bottom}.text-white.jsx-156758459{color:var(--primary)}/style>style id__jsx-420584599>.button.jsx-420584599{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-420584599::before{content:In-Person Event;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-420584599{height:0px}.pill.jsx-420584599::before{display:block;content:CME;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-420584599{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-420584599::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-420584599::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-420584599{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-420584599{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-420584599{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore4undefined.jsx-420584599:hover{background:var(--secondary)}.view-more-wrap4undefined.jsx-420584599{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap4undefined.jsx-420584599:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-420584599{background-position:right bottom}.text-white.jsx-420584599{color:var(--primary)}/style>style id__jsx-11414781>.button.jsx-11414781{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-11414781::before{content:Multimedia;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-11414781{height:0px}.pill.jsx-11414781::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-11414781{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-11414781::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-11414781::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-11414781{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-11414781{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-11414781{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore5undefined.jsx-11414781:hover{background:var(--secondary)}.view-more-wrap5undefined.jsx-11414781{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap5undefined.jsx-11414781:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-11414781{background-position:right bottom}.text-white.jsx-11414781{color:var(--primary)}/style>style id__jsx-3312281758>.button.jsx-3312281758{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-3312281758::before{content:Multimedia;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-3312281758{height:0px}.pill.jsx-3312281758::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-3312281758{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3312281758::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3312281758::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3312281758{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3312281758{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3312281758{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore6undefined.jsx-3312281758:hover{background:var(--secondary)}.view-more-wrap6undefined.jsx-3312281758{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap6undefined.jsx-3312281758:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3312281758{background-position:right bottom}.text-white.jsx-3312281758{color:var(--primary)}/style>style id__jsx-2926788927>.button.jsx-2926788927{height:0px;position:relative;z-index:999;bottom:176px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%)}.button.jsx-2926788927::before{content:Multimedia;display:block;position:relative;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:7.5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;z-index:99999999;background-color:var(--primary);color:white;bottom:69px;left:50%;-webkit-transform:translateX(-50%);-moz-transform:translateX(-50%);-ms-transform:translateX(-50%);-o-transform:translateX(-50%);transform:translateX(-50%);font-size:.75rem;text-align:center;line-height:1.15;max-width:200px}.pill.jsx-2926788927{height:0px}.pill.jsx-2926788927::before{display:block;content:CME, NCPD;height:22px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;background:var(--secondary);color:var(--primary);font-size:10px;font-weight:bold;padding:.25rem .5rem;text-align:center;-webkit-border-top-right-radius:15px;-moz-border-radius-topright:15px;border-top-right-radius:15px;-webkit-border-bottom-left-radius:15px;-moz-border-radius-bottomleft:15px;border-bottom-left-radius:15px;position:relative;float:right;bottom:413px;z-index:99}.bottomDiv.jsx-2926788927{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2926788927::before{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2926788927::after{content: ;display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2926788927{content: ;display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2926788927{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2926788927{position:absolute;width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;top:45%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore7undefined.jsx-2926788927:hover{background:var(--secondary)}.view-more-wrap7undefined.jsx-2926788927{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap7undefined.jsx-2926788927:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2926788927{background-position:right bottom}.text-white.jsx-2926788927{color:var(--primary)}/style>/head>body>div id__next data-reactroot>div class-mb-6>div classh-full w-full sticky top-0 z-999999>nav rolenavigation class w-full mx-auto hidden lg:block bg-white shadow-md relative>div classbg-white idtopnav>div classcontainer px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto >div classh-full flex items-center>a roleimg aria-labellogo classfocus:outline-none relative h-12 w-40 mr-6 flex items-center href/>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left/>noscript>img sizes100vw srcSet/_next/image?url%2FTargetedOnc_logo.png&w640&q75 640w, /_next/image?url%2FTargetedOnc_logo.png&w750&q75 750w, /_next/image?url%2FTargetedOnc_logo.png&w828&q75 828w, /_next/image?url%2FTargetedOnc_logo.png&w1080&q75 1080w, /_next/image?url%2FTargetedOnc_logo.png&w1200&q75 1200w, /_next/image?url%2FTargetedOnc_logo.png&w1920&q75 1920w, /_next/image?url%2FTargetedOnc_logo.png&w2048&q75 2048w, /_next/image?url%2FTargetedOnc_logo.png&w3840&q75 3840w src/_next/image?url%2FTargetedOnc_logo.png&w3840&q75 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left loadinglazy/>/noscript>/span>/a>div classhidden md:block>div classbg-white py-2 whitespace-nowrap>div classmx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl >div classflex gap-4>div class isolate z-10000  data-headlessui-state>button classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-gray-800 typebutton aria-expandedfalse data-headlessui-state>NEWSsvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>div classsr-only>a href/news/special-reports relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Special Reports/a>a href/news relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>All News/a>a href/fda-briefs relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>FDA Briefs/a>a href/oncology-icons relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Oncology Icons/a>a href/the-targeted-pulse relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>The Targeted Pulse/a>a href/news/voices-from-the-field relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Voices from the Field/a>/div>/div>div class isolate z-10000  data-headlessui-state>button classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-gray-800 typebutton aria-expandedfalse data-headlessui-state>CONFERENCESsvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>div classsr-only>a href/latest-conference relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Conference Coverage/a>a href/conference relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Conference Listing/a>a href/data-dialogue-with-the-oncology-brothers relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Data Dialogue with the Oncology Brothers/a>/div>/div>div class isolate z-10000  data-headlessui-state>button classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-gray-800 typebutton aria-expandedfalse data-headlessui-state>MEDIAsvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>div classsr-only>a href/videos relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>All Videos/a>a href/case-based-peer-perspectives relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Case-Based Peer Perspectives/a>a href/evolving-paradigms-in-oncology relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Evolving Paradigms in Oncology/a>a href/expert-perspective-tumor-board relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Expert Perspective Virtual Tumor Board/a>a href/interviews relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Interviews/a>a href/investigator-perspectives relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Investigator Perspectives/a>a hrefhttps://www.medicalworldnews.com/ relnoreferrer noopener target_blank classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Medical World News/a>a href/personalized-medicine-in relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Personalized Medicine/a>a href/pivotal-practice-views-with-the-oncology-brothers relnoreferrer noopener target_blank classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Pivotal Practice Views with the Oncology Brothers/a>a href/podcasts relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Podcasts/a>a href/speaking-out relnoreferrer noopener target_blank classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Speaking Out/a>/div>/div>div class isolate z-10000  data-headlessui-state>button classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-gray-800 typebutton aria-expandedfalse data-headlessui-state>PUBLICATIONSsvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>div classsr-only>a href/publications relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>All Publications/a>a href/publications/evolving-paradigms relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Evolving Paradigms/a>a href/publications/peers-perspectives-in-oncology relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Peers & Perspectives in Oncology/a>a href/publications/targeted-therapy-news relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Targeted Therapies in Oncology/a>/div>/div>a relnoopener target_self classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center  text-sm tracking-normal capitalize text-gray-800 href/case-based-roundtable-series>CASE-BASED ROUNDTABLE/a>a relnoopener target_self classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center  text-sm tracking-normal capitalize text-gray-800 href/partners>PARTNERS/a>div class isolate z-10000  data-headlessui-state>button classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-gray-800 typebutton aria-expandedfalse data-headlessui-state>RESOURCESsvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>div classsr-only>a href/continuing-education relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>CME/CE/a>a href/clinical-trials relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Clinical Trials/a>a href/events relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Events/a>a href/precision-medicine-perspectives relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Precision Medicine Perspectives/a>a href/press-releases relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Press Releases/a>a href/sponsored relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Sponsored Content/a>a href/treatment-resources relnoopener target_self classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>Treatment Resources/a>/div>/div>a relnoreferrer noopener target_blank classfocus:outline-none border-b-2 border-transparent font-medium cursor-pointer h-full flex items-center  text-sm tracking-normal capitalize text-gray-800 hrefhttps://one.targetedonc.com/subscribe>SUBSCRIBE/a>/div>/div>/div>/div>/div>div classmd:flex items-center justify-end hidden>div classflex items-center>div classmd:pr-10 lg:pr-0 h-full flex items-center>button classw-6 h-6 relative>svg xmlnshttp://www.w3.org/2000/svg classtext-gray-800 stroke-current icon icon-tabler icon-tabler-search viewBox0 0 24 24 stroke-width1.5 strokecurrentColor fillnone stroke-linecapround stroke-linejoinround>path strokenone dM0 0h24v24H0z>/path>circle cx10 cy10 r7>/circle>line x121 y121 x215 y215>/line>/svg>/button>div classhidden  bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center  z-99999 >form methodGET action/search>div classrelative>div classtext-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6>button aria-labelsubmit typesubmit classabsolute block inset-0>svg xmlnshttp://www.w3.org/2000/svg classtext-gray-600 stroke-current icon icon-tabler icon-tabler-search viewBox0 0 24 24 stroke-width2 strokecurrentColor fillnone stroke-linecapround stroke-linejoinround>path strokenone dM0 0h24v24H0z>/path>circle cx10 cy10 r7>/circle>line x121 y121 x215 y215>/line>/svg>/button>/div>input typetext required namesearchTerm classblock border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2 placeholderSearch/>/div>/form>/div>/div>/div>/div>/div>/div>div classbg-primary idbottomnav>div stylemax-height:50px classpx-4 transition-all container justify-between h-12 flex items-center md:items-stretch mx-auto>div classh-full w-full flex items-center justify-between relative>div classmin-w-170px z-1 mr-4>div classblock>div class>div classmx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl >div classflex gap-4 justify-start>div class isolate z-9999  data-headlessui-state>button classfocus:outline-none rounded font-medium cursor-pointer flex items-center  text-xs md:text-sm h-34px px-2 md:px-4 tracking-normal capitalize bg-white text-gray-600 typebutton aria-expandedfalse data-headlessui-state>Choose Specialtysvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>nav rolenavigation aria-labelChoose Specialty classsr-only>div>a relnoopener target_self href/clinical/brain classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BRAIN CANCER/a>/div>div>a relnoopener target_self href/clinical/breast classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BREAST CANCER/a>a relnoopener target_self href/clinical/breast classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BREAST CANCER/a>/div>div>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>/div>div>a relnoopener target_self href/clinical/genomic-testing classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENOMIC TESTING/a>a relnoopener target_self href/clinical/genomic-testing classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENOMIC TESTING/a>/div>div>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>/div>div>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>/div>div>a relnoopener target_self href/clinical/head-and-neck classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEAD & NECK CANCERS/a>/div>div>a relnoopener target_self href/clinical/hematology classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEMATOLOGY/a>a relnoopener target_self href/clinical/hematology classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEMATOLOGY/a>/div>div>a relnoopener target_self href/clinical/immunotherapy classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>IMMUNOTHERAPY/a>a relnoopener target_self href/clinical/immunotherapy classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>IMMUNOTHERAPY/a>/div>div>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>/div>div>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>/div>div>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>/div>div>a relnoopener target_self href/clinical/mpn classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>MPNs/a>/div>div>a relnoopener target_self href/clinical/multiple-myeloma-rc classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>MULTIPLE MYELOMA/a>/div>div>a relnoopener target_self href/clinical/ntrk classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>NTRK GENE FUSIONS/a>/div>div>a relnoopener target_self href/clinical/sarcoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SARCOMA/a>/div>div>a relnoopener target_self href/clinical/skin-cancers classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SKIN CANCERS/a>a relnoopener target_self href/clinical/skin-cancers classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SKIN CANCERS/a>/div>div>a relnoopener target_self href/clinical/thyroid classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>THYROID CANCERS/a>/div>/nav>/div>/div>/div>/div>/div>/div>div classflex flex-1 items-center overflow-hidden>span classtext-sm font-bold mr-1 whitespace-pre text-gray-50>Spotlight - /span>ul idspotlight-links classflex gap-2 h-4 overflow-hidden flex-wrap>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/multiple-myeloma-rc>Myeloma/a>/li>span classborder-r w-0 border-gray-400>/span>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/cll>Chronic Lymphocytic Leukemia/a>/li>span classborder-r w-0 border-gray-400>/span>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/gynecologic>Gynecologic Cancers/a>/li>span classborder-r w-0 border-gray-400>/span>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/genomic-testing>Genomic Testing/a>/li>span classborder-r w-0 border-gray-400>/span>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/melanoma>Melanoma/a>/li>span classborder-r w-0 border-gray-400>/span>li classtext-xs underline whitespace-pre cursor-pointer text-blue-200>a target rel href/clinical/genitourinary>Genitourinary Cancers/a>/li>/ul>/div>/div>/div>/div>/nav>nav classlg:hidden>div classw-full shadow-md bg-white sticky top-0 z-40>div classflex mx-auto container>div class py-4 flex items-stretch justify-between mx-4 items-center w-full>div classflex items-center justify-end>div classflex items-center>div classh-full flex items-center>button idmenu aria-labelopen menu aria-expandedfalse classfocus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md  text-gray-800>svg width30 height30 viewBox0 0 24 24 fillnone xmlnshttp://www.w3.org/2000/svg>path dM21 10H3 stroke#4B5563 stroke-width1.5 stroke-linecapround stroke-linejoinround>/path>path dM21 6H3 stroke#4B5563 stroke-width1.5 stroke-linecapround stroke-linejoinround>/path>path dM21 14H3 stroke#4B5563 stroke-width1.5 stroke-linecapround stroke-linejoinround>/path>path dM21 18H3 stroke#4B5563 stroke-width1.5 stroke-linecapround stroke-linejoinround>/path>/svg>/button>/div>/div>/div>div aria-labellogo roleimg tabindex0 classfocus:outline-none relative h-10 w-40>a roleimg aria-labellogo classfocus:outline-none relative h-12 w-40 mr-6 flex items-center href/>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center/>noscript>img sizes100vw srcSet/_next/image?url%2FTargetedOnc_logo.png&w640&q75 640w, /_next/image?url%2FTargetedOnc_logo.png&w750&q75 750w, /_next/image?url%2FTargetedOnc_logo.png&w828&q75 828w, /_next/image?url%2FTargetedOnc_logo.png&w1080&q75 1080w, /_next/image?url%2FTargetedOnc_logo.png&w1200&q75 1200w, /_next/image?url%2FTargetedOnc_logo.png&w1920&q75 1920w, /_next/image?url%2FTargetedOnc_logo.png&w2048&q75 2048w, /_next/image?url%2FTargetedOnc_logo.png&w3840&q75 3840w src/_next/image?url%2FTargetedOnc_logo.png&w3840&q75 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center loadinglazy/>/noscript>/span>/a>/div>div classrelative w-8 h-8 my grid items-center>a classabsolute lg:hidden inset-0 mt-1 href/search>svg xmlnshttp://www.w3.org/2000/svg classtext-gray-800 stroke-current icon icon-tabler icon-tabler-search viewBox0 0 24 24 stroke-width1.5 strokecurrentColor fillnone stroke-linecapround stroke-linejoinround>path strokenone dM0 0h24v24H0z>/path>circle cx10 cy10 r7>/circle>line x121 y121 x215 y215>/line>/svg>/a>/div>/div>/div>div stylemax-height:50px classbg-primary px-4 transition-all  h-12  md:items-stretch mx-auto idbottomnav-mobile>div classcontainer justify-between h-12 flex items-center md:items-stretch mx-auto>div classh-full w-full flex items-center justify-between relative>div classflex flex-1 justify-center xs:justify-start items-center relative group h-full z-50>div classz-1>div classblock>div class>div classmx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl >div classflex gap-4 justify-start>div class isolate z-9999  data-headlessui-state>button classfocus:outline-none rounded font-medium cursor-pointer flex items-center  text-xs md:text-sm h-34px px-2 md:px-4 tracking-normal capitalize bg-white text-gray-600 typebutton aria-expandedfalse data-headlessui-state>Choose Specialtysvg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 height1em width1em xmlnshttp://www.w3.org/2000/svg>path dm11.998 17 7-8h-14z>/path>/svg>/button>nav rolenavigation aria-labelChoose Specialty classsr-only>div>a relnoopener target_self href/clinical/brain classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BRAIN CANCER/a>/div>div>a relnoopener target_self href/clinical/breast classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BREAST CANCER/a>a relnoopener target_self href/clinical/breast classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>BREAST CANCER/a>/div>div>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>a relnoopener target_self href/clinical/genitourinary classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENITOURINARY CANCERS/a>/div>div>a relnoopener target_self href/clinical/genomic-testing classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENOMIC TESTING/a>a relnoopener target_self href/clinical/genomic-testing classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GENOMIC TESTING/a>/div>div>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>a relnoopener target_self href/clinical/gastrointestinal classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GI CANCERS/a>/div>div>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>a relnoopener target_self href/clinical/gynecologic classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>GYNECOLOGIC CANCERS/a>/div>div>a relnoopener target_self href/clinical/head-and-neck classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEAD & NECK CANCERS/a>/div>div>a relnoopener target_self href/clinical/hematology classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEMATOLOGY/a>a relnoopener target_self href/clinical/hematology classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>HEMATOLOGY/a>/div>div>a relnoopener target_self href/clinical/immunotherapy classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>IMMUNOTHERAPY/a>a relnoopener target_self href/clinical/immunotherapy classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>IMMUNOTHERAPY/a>/div>div>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>a relnoopener target_self href/clinical/leukemias classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LEUKEMIAS/a>/div>div>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>a relnoopener target_self href/clinical/lung classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LUNG CANCER/a>/div>div>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>a relnoopener target_self href/clinical/lymphoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>LYMPHOMAS/a>/div>div>a relnoopener target_self href/clinical/mpn classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>MPNs/a>/div>div>a relnoopener target_self href/clinical/multiple-myeloma-rc classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>MULTIPLE MYELOMA/a>/div>div>a relnoopener target_self href/clinical/ntrk classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>NTRK GENE FUSIONS/a>/div>div>a relnoopener target_self href/clinical/sarcoma classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SARCOMA/a>/div>div>a relnoopener target_self href/clinical/skin-cancers classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SKIN CANCERS/a>a relnoopener target_self href/clinical/skin-cancers classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>SKIN CANCERS/a>/div>div>a relnoopener target_self href/clinical/thyroid classflex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline>THYROID CANCERS/a>/div>/nav>/div>/div>/div>/div>/div>/div>/div>/div>/div>/div>/div>div classfixed top-0 w-85vw h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg idmobile-nav>div classw-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out>div classpx-5 h-full>div classflex flex-col justify-between h-full w-full>div>div classmt-6 flex w-full items-center justify-between>div classborder-b border-gray-200 pb-2 flex items-center justify-between w-full>div aria-labellogo roleimg tabindex0 classfocus:outline-none relative h-16 w-40 >span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left/>noscript>img sizes100vw srcSet/_next/image?url%2Flog_inverted.png&w640&q75 640w, /_next/image?url%2Flog_inverted.png&w750&q75 750w, /_next/image?url%2Flog_inverted.png&w828&q75 828w, /_next/image?url%2Flog_inverted.png&w1080&q75 1080w, /_next/image?url%2Flog_inverted.png&w1200&q75 1200w, /_next/image?url%2Flog_inverted.png&w1920&q75 1920w, /_next/image?url%2Flog_inverted.png&w2048&q75 2048w, /_next/image?url%2Flog_inverted.png&w3840&q75 3840w src/_next/image?url%2Flog_inverted.png&w3840&q75 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left loadinglazy/>/noscript>/span>/div>button aria-labelclose menu classfocus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold>svg width18 height18 viewBox0 0 14 14 fill#fff xmlnshttp://www.w3.org/2000/svg>path dM13 1L1 13 stroke#fff stroke-linecapround stroke-width2 stroke-linejoinround>/path>path dM1 1L13 13 stroke#fff stroke-linecapround stroke-width2 stroke-linejoinround>/path>/svg>/button>/div>/div>ul rolelist classflex flex-1 flex-col gap-y-7 mt-6>li>ul rolelist class-mx-2 space-y-1>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>Spotlight/button>/div>/li>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>NEWS/button>/div>/li>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>CONFERENCES/button>/div>/li>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>MEDIA/button>/div>/li>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>PUBLICATIONS/button>/div>/li>li>a classhover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50 href/case-based-roundtable-series>span>CASE-BASED ROUNDTABLE/span>/a>/li>li>a classhover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50 href/partners>span>PARTNERS/span>/a>/li>li>div data-headlessui-state>button classhover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50 idheadlessui-disclosure-button-undefined typebutton aria-expandedfalse data-headlessui-state>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 320 512 classtext-gray-50 h-5 w-5 shrink-0 aria-hiddentrue height1em width1em xmlnshttp://www.w3.org/2000/svg>path dM285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z>/path>/svg>RESOURCES/button>/div>/li>li>a classhover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50 hrefhttps://one.targetedonc.com/subscribe>span>SUBSCRIBE/span>/a>/li>/ul>/li>/ul>div classflex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t>a relnoreferrer noopener target_blank hrefhttps://www.facebook.com/TargetedOnc/>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 448 512 color#fff stylecolor:#fff height24 width24 xmlnshttp://www.w3.org/2000/svg>path dM400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z>/path>/svg>/a>a relnoreferrer noopener target_blank hrefhttps://www.linkedin.com/company/targetedonc>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 448 512 color#fff stylecolor:#fff height27 width27 xmlnshttp://www.w3.org/2000/svg>path dM416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z>/path>/svg>/a>a relnoreferrer noopener target_blank hrefhttps://twitter.com/TargetedOnc>/a>a relnoreferrer noopener target_blank hrefhttps://www.youtube.com/user/TargetedHC>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 576 512 color#fff stylecolor:#fff height32 width32 xmlnshttp://www.w3.org/2000/svg>path dM549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z>/path>/svg>/a>a relnoreferrer noopener target_blank hrefhttps://www.instagram.com/targetedoncology/>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 448 512 color#fff stylecolor:#fff height24 width24 xmlnshttp://www.w3.org/2000/svg>path dM224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z>/path>/svg>/a>/div>/div>/div>/div>/div>/div>/nav>/div>div class relative bg-primary xs:top-0 flex justify-center items-center  border-b border-gray-300 shadow-0_2px_5px_rgba(0,0,0,0.25)  w-full mt-4.25rem sm:mt-0 transition-all duration-500 ease-in-out overflow-visible -mb-20 xs:mb-0 !z-50>div classcontainer w-full flex flex-col md:flex-row items-center gap-4 md:gap-12 my-0 md:my-0 ml-4 mr-4 >div classflex-row items-center hidden md:flex>button classcursor-pointer w-1/2 md:w-full h-full flex items-center justify-center md:justify-start px-4 relative>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27100%27%20height%27120%27/%3e/>/span>img altscout srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic classanimate-fade !duration-300 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altscout srcSet/_next/image?url%2FTO_SCOUT-head-name%201.png&w128&q75 1x, /_next/image?url%2FTO_SCOUT-head-name%201.png&w256&q75 2x src/_next/image?url%2FTO_SCOUT-head-name%201.png&w256&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classanimate-fade !duration-300 loadinglazy/>/noscript>/span>p classbeta text-white text-xs font-bold mb-90px animate-fade !duration-300>BETA/p>/button>p class text-center text-white font-thin mt-2 mb-2 xxs:mt-0 md:mb-4 >Your AI-Trained Oncology Knowledge Connection!/p>/div>div classw-full md:px-0 cursor-pointer z-10 relative>div classinput-container w-full flex justify-center items-center md:block md:w-auto gap-8 md:px-0>div classblock md:hidden pt-2>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%2750%27%20height%2760%27/%3e/>/span>img altscout srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic classhidden object-contain styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altscout srcSet/_next/image?url%2FTO_SCOUT-head-name%201.png&w64&q75 1x, /_next/image?url%2FTO_SCOUT-head-name%201.png&w128&q75 2x src/_next/image?url%2FTO_SCOUT-head-name%201.png&w128&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classhidden object-contain loadinglazy/>/noscript>/span>/div>div classrelative w-full>div classmin-w-60% relative flex-1 h-10 md:h-50px bg-white rounded-full text-gray-500 italic flex items-center justify-start border-none outline-none text-sm md:text-base px-4 xs:px-6 pr-4>/div>button classabsolute right-2 top-2 md:top-3>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%2724%27%20height%2724%27/%3e/>/span>img altsearch srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altsearch srcSet/_next/image?url%2Fyellow_button.svg&w32&q75 1x, /_next/image?url%2Fyellow_button.svg&w48&q75 2x src/_next/image?url%2Fyellow_button.svg&w48&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% loadinglazy/>/noscript>/span>/button>/div>/div>/div>/div>/div>div classscout-open-container w-full h-full overflow-hidden max-w-screen xs:mt-0 fixed top-0 left-0 right-0 z-999999999 bg-white transition-all  max-h-0 transition-max-height duration-.5s ease-in>div classmin-h-screen grid place-items-center>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 512 512 classtext-gray-500 bg-transparent absolute top-2 right-2 cursor-pointer z-50 height2rem width2rem xmlnshttp://www.w3.org/2000/svg>path fillnone stroke-miterlimit10 stroke-width32 dM448 256c0-106-86-192-192-192S64 150 64 256s86 192 192 192 192-86 192-192z>/path>path fillnone stroke-linecapround stroke-linejoinround stroke-width32 dM320 320L192 192m0 128l128-128>/path>/svg>div classrelative w-full h-full>/div>/div>/div>div classcontainer top-ad-div px-4 mx-auto pl-2 pr-2 sm:h-98px sm:w-728px>div idleaderboardWrapper classjsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-90px justify-center items-center flex-col relative z-99999  >div classjsx-1661e6713d4eb9b5 bg-white md:-translate-x-4>div classjsx-1661e6713d4eb9b5 text-8px text-center text-gray-600 hidden relative>Advertisement/div>div iddiv-gpt-ad-top classjsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x>/div>/div>/div>/div>hr classmt-8 pt-8 -mb-4 pb-0 customPageTopMargin/>div id classstudy-hall customPageFullWidthClass container mx-auto flex m-1 min-h-57vh px-4>div classcustomPageFullWidthClass flex-auto w-calc(100%-300px) pr-0 md:pr-6 mt-16 sm:mt-0>div classm-2>h2 classtext-3xl>Latest News/h2>div classw-full border-b border-secondary>/div>div classgrid gap-2 md:gap-4 grid-cols-1 md:grid-cols-2>div classflex mt-4 col-span-2>a classflex-none w-32% mr-.75rem mt-4 sm:w-60 md:mt-3 href/view/blood-based-monitoring-assay-predicts-immunotherapy-response-in-advanced-cancers>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altBlood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers titleBlood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altBlood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers titleBlood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fbf401f08b58804d8aa322d18ed8162f17a886f20-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classflex-auto py-2 border-t-2 border-t-gray-100>div>a classfont-bold href/view/blood-based-monitoring-assay-predicts-immunotherapy-response-in-advanced-cancers>Blood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers/a>/div>div classpb-2>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>/div>a href/view/blood-based-monitoring-assay-predicts-immunotherapy-response-in-advanced-cancers>span classtext-sm text-gray-500>August 3rd 2025/span>/a>/div>/div>div classflex mt-4 col-span-2 md:col-span-1>a classflex-none w-32% mr-1rem md:w-32 mt-4 href/view/targeted-pulse-august-3>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altThe Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology titleThe Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altThe Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology titleThe Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classflex-auto py-2 border-t-2 border-t-gray-100>div>a classfont-bold href/view/targeted-pulse-august-3>The Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology/a>/div>div classpb-2>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/targeted-oncology-staff>Targeted Oncology Staff/a>/span>/div>/div>a href/view/targeted-pulse-august-3>span classtext-sm text-gray-500>August 3rd 2025/span>/a>/div>/div>div classflex mt-4 col-span-2 md:col-span-1>a classflex-none w-32% mr-1rem md:w-32 mt-4 href/view/breast-cancer-trial-investigates-personalized-neoadjuvant-therapy>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img alt Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy title Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img alt Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy title Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classflex-auto py-2 border-t-2 border-t-gray-100>div>a classfont-bold href/view/breast-cancer-trial-investigates-personalized-neoadjuvant-therapy> Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy/a>/div>div classpb-2>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>/div>a href/view/breast-cancer-trial-investigates-personalized-neoadjuvant-therapy>span classtext-sm text-gray-500>August 2nd 2025/span>/a>/div>/div>div classflex mt-4 col-span-2 md:col-span-1>a classflex-none w-32% mr-1rem md:w-32 mt-4 href/view/stride-regimen-shows-sustained-5-year-os-benefit-in-unresectable-hcc>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.041666666666664%>/span>img altSTRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC titleSTRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altSTRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC titleSTRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F043eaa7256c7938046b287a4b9c883327737332a-480x269.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classflex-auto py-2 border-t-2 border-t-gray-100>div>a classfont-bold href/view/stride-regimen-shows-sustained-5-year-os-benefit-in-unresectable-hcc>STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC/a>/div>div classpb-2>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>/div>a href/view/stride-regimen-shows-sustained-5-year-os-benefit-in-unresectable-hcc>span classtext-sm text-gray-500>August 2nd 2025/span>/a>/div>/div>div classflex mt-4 col-span-2 md:col-span-1>a classflex-none w-32% mr-1rem md:w-32 mt-4 href/view/sustained-benefit-in-advanced-rcc-with-pembrolizumab-and-axitinib>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altSustained Benefit in Advanced RCC with Pembrolizumab and Axitinib titleSustained Benefit in Advanced RCC with Pembrolizumab and Axitinib srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altSustained Benefit in Advanced RCC with Pembrolizumab and Axitinib titleSustained Benefit in Advanced RCC with Pembrolizumab and Axitinib sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classflex-auto py-2 border-t-2 border-t-gray-100>div>a classfont-bold href/view/sustained-benefit-in-advanced-rcc-with-pembrolizumab-and-axitinib>Sustained Benefit in Advanced RCC with Pembrolizumab and Axitinib/a>/div>div classpb-2>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>/div>a href/view/sustained-benefit-in-advanced-rcc-with-pembrolizumab-and-axitinib>span classtext-sm text-gray-500>August 1st 2025/span>/a>/div>/div>/div>/div>div classjsx-19ede9f0a5a45918  py-4 relative px-0>div classjsx-19ede9f0a5a45918 >div classflex justify-between items-center py-1 space-x-4 border-0 select-none sm:border-b border-secondary>div classtext-3xl text-primary >Latest Videos/div>/div>/div>div stylescroll-snap-type:none classjsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-calc(100%-64px)>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/frontline-metastatic-rcc-therapy-improved-with-long-term-data>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png%2FMcGregor%2520TN.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/transform-trial-clinical-perspectives-in-liso-cel-car-t-cell-therapy-for-second-line-r-r-lbcl>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/the-evolving-mpn-landscape-future-therapeutic-directions-and-addressing-unmet-needs-in-myelofibrosis-and-polycythemia-vera>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/the-future-of-dato-dxd-in-lung-cancer-and-beyond>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/implementation-strategies-real-world-treatment-implementation>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png%2FTarantinoHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/the-evolving-role-of-lenvatinib-in-the-hcc-therapeutic-landscape>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png%2Fmarketing%2520image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/the-future-of-dato-dxd-in-lung-cancer-and-beyond>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/toxicity-management-for-dato-dxd-stomatitis-eye-issues-and-ild>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/future-horizons-in-scac-current-standards-and-next-generation-treatment-strategies>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png%2FMarketing%2520Image%2520(27).png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/behind-the-fda-approval-of-dato-dxd-in-lung-cancer-with-dr-sands>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png%2FSands%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/transform-trial-clinical-perspectives-in-liso-cel-car-t-cell-therapy-for-second-line-r-r-lbcl>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/car-t-in-practice-translating-zuma-7-trial-data-for-axi-cel-in-second-line-treatment-decisions>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png%2FOluwoleHS.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/fertility-preservation-in-patients-with-cancer-key-takeaways-for-oncologists>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/challenges-of-access-to-fertility-preservation-in-the-us>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff745d66774d828898d4c380047f710dd34962fe2-1200x630.png%2FMcDaniel%2520thumb.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/breaking-barriers-future-directions-in-cll-sll-treatment>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/real-world-use-of-frontline-btk-inhibitor-therapies>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/expert-insights-emerging-combination-strategies-in-treatment-naive-cll>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/comprehensive-approaches-for-managing-therapeutic-safety-in-tn-cll>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/mrd-guided-therapy-current-and-future-practices>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/evidence-based-strategies-for-frontline-therapies-in-tn-cll>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>a id classw-200px h-fit space-y-3 flex-none select-none no-underline stylescroll-snap-align:center;text-decoration:none href/view/zanubrutinib-in-tn-cll-expert-insights-on-latest-data-from-sequoia-arm-c>div classw-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0>img alt title srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain/>noscript>img alt title sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q30 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q30 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q30 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q30 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q30 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q30 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q30 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fc3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png%2FScreenshot%25202025-07-25%2520at%252012.32.01%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q30 decodingasync data-nimgfill styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain loadinglazy/>/noscript>/span>/div>div classw-full flex-wrap text-center text-sm mt-4 font-light no-underline line-clamp-3 text-gray-700>/div>/a>/div>/div>div classjsx-19ede9f0a5a45918  py-4 relative px-0>div classjsx-19ede9f0a5a45918 >div classflex justify-between items-center py-1 space-x-4 border-0 select-none sm:border-b border-secondary>div classtext-primary text-3xl>Continuing Medical Education/div>/div>/div>div stylescroll-snap-type:none classjsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-full md:w-calc(100%-64px)>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-1588017350 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/pers-satellite-symposia-at-mhs?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-1588017350 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-1588017350 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fanp0ybypdb9j-MSHGenericTICatalog750x361.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fanp0ybypdb9j-MSHGenericTICatalog750x361.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fanp0ybypdb9j-MSHGenericTICatalog750x361.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-1588017350 bottomDiv>/div>div classjsx-1588017350 border-div>/div>div classjsx-1588017350 pill>/div>noscript classjsx-1588017350>In-Person Event/noscript>noscript classjsx-1588017350>CME, NCPD/noscript>div classjsx-1588017350 content-wrap>div classjsx-1588017350 w-full h-fit mb-4>p classjsx-1588017350 text-xs px-4 text-center text-#39485F font-bold>PER's Satellite Symposia at MHS/p>/div>p classjsx-1588017350 text-center text-xs font-semibold px-4>August 1-2, 2025/p>/div>div classjsx-1588017350 view-more-wrap0undefined>div classjsx-1588017350 flex justify-center w-50%>p idviewMoreText0undefined classjsx-1588017350 text-sm text-#ffffff>Register Now!/p>/div>div idviewMore0undefined classjsx-1588017350 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-1588017350>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-1588017350 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-4267007461 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/24th-annual-international-congress-on-the-future-of-breast-cancer-east?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-4267007461 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-4267007461 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F7gyyfqzcd5vy-IBC25EASTRAPIDWebcardV2_TICatalog750x361.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F7gyyfqzcd5vy-IBC25EASTRAPIDWebcardV2_TICatalog750x361.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fmedia.thoughtindustries.com%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F7gyyfqzcd5vy-IBC25EASTRAPIDWebcardV2_TICatalog750x361.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-4267007461 bottomDiv>/div>div classjsx-4267007461 border-div>/div>div classjsx-4267007461 pill>/div>noscript classjsx-4267007461>Video/noscript>noscript classjsx-4267007461>CME, NCPD/noscript>div classjsx-4267007461 content-wrap>div classjsx-4267007461 w-full h-fit mb-4>p classjsx-4267007461 text-xs px-4 text-center text-#39485F font-bold>24th Annual International Congress on the Future of Breast Cancer® East/p>/div>/div>div classjsx-4267007461 view-more-wrap1undefined>div classjsx-4267007461 flex justify-center w-50%>p idviewMoreText1undefined classjsx-4267007461 text-sm text-#ffffff>View More/p>/div>div idviewMore1undefined classjsx-4267007461 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-4267007461>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-4267007461 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-1229105766 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/differentiating-adverse-events-for-antibody-drug-conjugates-across-solid-tumor-management-cuq0?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-1229105766 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-1229105766 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fldmdft6xfk42-SONO24_InlineSession_ADC_Archive_TICatalog750x3611.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fldmdft6xfk42-SONO24_InlineSession_ADC_Archive_TICatalog750x3611.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fldmdft6xfk42-SONO24_InlineSession_ADC_Archive_TICatalog750x3611.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-1229105766 bottomDiv>/div>div classjsx-1229105766 border-div>/div>div classjsx-1229105766 pill>/div>noscript classjsx-1229105766>Video/noscript>noscript classjsx-1229105766>CME, NCPD/noscript>div classjsx-1229105766 content-wrap>div classjsx-1229105766 w-full h-fit mb-4>p classjsx-1229105766 text-xs px-4 text-center text-#39485F font-bold>Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management/p>/div>/div>div classjsx-1229105766 view-more-wrap2undefined>div classjsx-1229105766 flex justify-center w-50%>p idviewMoreText2undefined classjsx-1229105766 text-sm text-#ffffff>View More/p>/div>div idviewMore2undefined classjsx-1229105766 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-1229105766>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-1229105766 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-156758459 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/community-practice-connections-23rd-annual-international-congress-on-the-future-of-breast-cancer-west?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-156758459 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-156758459 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fqau5c908qo6p-750x3612x31.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fqau5c908qo6p-750x3612x31.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fqau5c908qo6p-750x3612x31.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-156758459 bottomDiv>/div>div classjsx-156758459 border-div>/div>div classjsx-156758459 pill>/div>noscript classjsx-156758459>Multimedia/noscript>noscript classjsx-156758459>CME, NCPD/noscript>div classjsx-156758459 content-wrap>div classjsx-156758459 w-full h-fit mb-4>p classjsx-156758459 text-xs px-4 text-center text-#39485F font-bold>  Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West/p>/div>/div>div classjsx-156758459 view-more-wrap3undefined>div classjsx-156758459 flex justify-center w-50%>p idviewMoreText3undefined classjsx-156758459 text-sm text-#ffffff>View More/p>/div>div idviewMore3undefined classjsx-156758459 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-156758459>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-156758459 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-420584599 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/school-of-breast-oncology?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-420584599 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-420584599 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fyz3v1oafy7yp-SOBO25_WebBanners_TICatalog750x361.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fyz3v1oafy7yp-SOBO25_WebBanners_TICatalog750x361.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fyz3v1oafy7yp-SOBO25_WebBanners_TICatalog750x361.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-420584599 bottomDiv>/div>div classjsx-420584599 border-div>/div>div classjsx-420584599 pill>/div>noscript classjsx-420584599>In-Person Event/noscript>noscript classjsx-420584599>CME/noscript>div classjsx-420584599 content-wrap>div classjsx-420584599 w-full h-fit mb-4>p classjsx-420584599 text-xs px-4 text-center text-#39485F font-bold>23rd Annual School of Breast Oncology/p>/div>p classjsx-420584599 text-center text-xs font-semibold px-4>November 6-8, 2025/p>/div>div classjsx-420584599 view-more-wrap4undefined>div classjsx-420584599 flex justify-center w-50%>p idviewMoreText4undefined classjsx-420584599 text-sm text-#ffffff>Register Now!/p>/div>div idviewMore4undefined classjsx-420584599 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-420584599>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-420584599 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-11414781 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/community-practice-connections-navigating-early-stage-hrher2-breast-cancer-clinical-developments-and-innovative-treatments?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-11414781 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-11414781 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fj71l23fiym7b-TICatalog750x3612x1811.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fj71l23fiym7b-TICatalog750x3612x1811.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fj71l23fiym7b-TICatalog750x3612x1811.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-11414781 bottomDiv>/div>div classjsx-11414781 border-div>/div>div classjsx-11414781 pill>/div>noscript classjsx-11414781>Multimedia/noscript>noscript classjsx-11414781>CME, NCPD/noscript>div classjsx-11414781 content-wrap>div classjsx-11414781 w-full h-fit mb-4>p classjsx-11414781 text-xs px-4 text-center text-#39485F font-bold>Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments/p>/div>/div>div classjsx-11414781 view-more-wrap5undefined>div classjsx-11414781 flex justify-center w-50%>p idviewMoreText5undefined classjsx-11414781 text-sm text-#ffffff>View More/p>/div>div idviewMore5undefined classjsx-11414781 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-11414781>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-11414781 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-3312281758 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/community-practice-connections-community-oncologists-role-in-selecting-optimal-oral-serd-treatment-for-hrher2-breast-cancer?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-3312281758 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-3312281758 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F4ph3yo50ru8x-CoC_SERDS_CPCWebBanners_TICatalog750x3611.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F4ph3yo50ru8x-CoC_SERDS_CPCWebBanners_TICatalog750x3611.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2F4ph3yo50ru8x-CoC_SERDS_CPCWebBanners_TICatalog750x3611.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-3312281758 bottomDiv>/div>div classjsx-3312281758 border-div>/div>div classjsx-3312281758 pill>/div>noscript classjsx-3312281758>Multimedia/noscript>noscript classjsx-3312281758>CME, NCPD/noscript>div classjsx-3312281758 content-wrap>div classjsx-3312281758 w-full h-fit mb-4>p classjsx-3312281758 text-xs px-4 text-center text-#39485F font-bold>Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer/p>/div>/div>div classjsx-3312281758 view-more-wrap6undefined>div classjsx-3312281758 flex justify-center w-50%>p idviewMoreText6undefined classjsx-3312281758 text-sm text-#ffffff>View More/p>/div>div idviewMore6undefined classjsx-3312281758 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-3312281758>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-3312281758 button>/div>/a>a target_blank stylescroll-snap-align:center;text-decoration:none classjsx-2926788927 w-250px h-350px flex flex-col space-y-3 flex-none select-none no-underline href/redirect?urlhttps://www.gotoper.com/courses/community-practice-connections-case-discussions-in-tnbc-navigating-the-latest-advances-and-impact-of-disparities-in-care?utm_sourcetargetedoncology&utm_mediumhomePage&utm_campaigncmeDeck>div classjsx-2926788927 w-full h-full flex flex-col rounded-b-10px rounded-t-15px overflow-hidden relative  bg-white shadow-0_3px_7px_0px_#37393d>div classjsx-2926788927 relative rounded-t-15px>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27250%27%20height%27125%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill/>noscript>img alt srcSet/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fy8ph9goqn3tw-TICatalog750x3612x322.png&w256&q75 1x, /_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fy8ph9goqn3tw-TICatalog750x3612x322.png&w640&q75 2x src/_next/image?urlhttps%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2F07c0d4e1-23aa-4e1a-8c5f-f2569da581c0%2Fy8ph9goqn3tw-TICatalog750x3612x322.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:fill loadinglazy/>/noscript>/span>/div>div classjsx-2926788927 bottomDiv>/div>div classjsx-2926788927 border-div>/div>div classjsx-2926788927 pill>/div>noscript classjsx-2926788927>Multimedia/noscript>noscript classjsx-2926788927>CME, NCPD/noscript>div classjsx-2926788927 content-wrap>div classjsx-2926788927 w-full h-fit mb-4>p classjsx-2926788927 text-xs px-4 text-center text-#39485F font-bold>Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care/p>/div>/div>div classjsx-2926788927 view-more-wrap7undefined>div classjsx-2926788927 flex justify-center w-50%>p idviewMoreText7undefined classjsx-2926788927 text-sm text-#ffffff>View More/p>/div>div idviewMore7undefined classjsx-2926788927 flex w-15% h-full justify-center items-center bg-secondary z-9999>div classjsx-2926788927>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 stylecolor:var(--primary);width:100%;height:100% height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8z>/path>/svg>/div>/div>/div>/div>div classjsx-2926788927 button>/div>/a>/div>/div>div classm-2>h2 classtext-3xl>All Community Oncology News/h2>div classw-full border border-secondary>/div>div classgrid gap-2 md:gap-4 grid-cols-1>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/rethinking-rectal-cancer-end-points-pcr-not-a-survival-surrogate>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altRethinking Rectal Cancer End Points: pCR Not a Survival Surrogate titleRethinking Rectal Cancer End Points: pCR Not a Survival Surrogate srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altRethinking Rectal Cancer End Points: pCR Not a Survival Surrogate titleRethinking Rectal Cancer End Points: pCR Not a Survival Surrogate sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/rethinking-rectal-cancer-end-points-pcr-not-a-survival-surrogate>Rethinking Rectal Cancer End Points: pCR Not a Survival Surrogate/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/rethinking-rectal-cancer-end-points-pcr-not-a-survival-surrogate>span classtext-sm text-gray-500>August 1st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/advancing-prostate-cancer-treatment-with-shared-decision-making>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altAdvancing Prostate Cancer Treatment With Shared Decision-Making titleAdvancing Prostate Cancer Treatment With Shared Decision-Making srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altAdvancing Prostate Cancer Treatment With Shared Decision-Making titleAdvancing Prostate Cancer Treatment With Shared Decision-Making sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/advancing-prostate-cancer-treatment-with-shared-decision-making>Advancing Prostate Cancer Treatment With Shared Decision-Making/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/benjamin-garmezy-md>Benjamin Garmezy, MD/a>/span>span classtext-md >span classmr-1 italic>br/>/span>a classmr-1 text-sky-800 hover:text-primary href/authors/ralph-j-miller-jr-md>Ralph J. Miller Jr, MD/a>/span>/div>a href/view/advancing-prostate-cancer-treatment-with-shared-decision-making>span classtext-sm text-gray-500>August 1st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex md:hidden justify-center items-center>/div>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/july-2025-fda-news>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altJuly's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements titleJuly's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altJuly's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements titleJuly's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/july-2025-fda-news>July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/targeted-oncology-staff>Targeted Oncology Staff/a>/span>/div>a href/view/july-2025-fda-news>span classtext-sm text-gray-500>August 1st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/cabozantinib-atezolizumab-improves-pfs-in-patients-with-mcrpc-and-extrapelvic-metastases>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altCabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases titleCabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altCabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases titleCabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/cabozantinib-atezolizumab-improves-pfs-in-patients-with-mcrpc-and-extrapelvic-metastases>Cabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/tony-berberabe-mph>Tony Berberabe, MPH/a>/span>/div>a href/view/cabozantinib-atezolizumab-improves-pfs-in-patients-with-mcrpc-and-extrapelvic-metastases>span classtext-sm text-gray-500>August 1st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/novel-gprc5d-mab-receives-fda-orphan-drug-designation-in-r-r-myeloma>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altNovel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma titleNovel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altNovel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma titleNovel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/novel-gprc5d-mab-receives-fda-orphan-drug-designation-in-r-r-myeloma>Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/novel-gprc5d-mab-receives-fda-orphan-drug-designation-in-r-r-myeloma>span classtext-sm text-gray-500>July 31st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/novel-combinations-show-promise-in-resectable-nsclc-led-by-adc-chemo-immuno-triplet>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altNovel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet titleNovel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altNovel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet titleNovel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Facece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/novel-combinations-show-promise-in-resectable-nsclc-led-by-adc-chemo-immuno-triplet>Novel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/novel-combinations-show-promise-in-resectable-nsclc-led-by-adc-chemo-immuno-triplet>span classtext-sm text-gray-500>July 31st 2025/span>div classmt-2>/div>div classpy-1 text-sm text-gray-500>div classblockText_blockContent__TbCXh>/div>/div>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/gedatolisib-shows-impressive-pfs-in-hr-her2-breast-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altGedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer titleGedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altGedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer titleGedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/gedatolisib-shows-impressive-pfs-in-hr-her2-breast-cancer>Gedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/gedatolisib-shows-impressive-pfs-in-hr-her2-breast-cancer>span classtext-sm text-gray-500>July 31st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/advancing-metastatic-breast-cancer-treatment-z-endoxifen-nears-ind-submission>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altAdvancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission titleAdvancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altAdvancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission titleAdvancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/advancing-metastatic-breast-cancer-treatment-z-endoxifen-nears-ind-submission>Advancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/advancing-metastatic-breast-cancer-treatment-z-endoxifen-nears-ind-submission>span classtext-sm text-gray-500>July 31st 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization and combination therapy strategies./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex md:hidden justify-center items-center>/div>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/elimination-of-rems-program-could-reduce-barriers-to-car-t-in-dlbcl>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:55.01325088339223%>/span>img altElimination of REMS Program Could Reduce Barriers to CAR T in DLBCL titleElimination of REMS Program Could Reduce Barriers to CAR T in DLBCL srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altElimination of REMS Program Could Reduce Barriers to CAR T in DLBCL titleElimination of REMS Program Could Reduce Barriers to CAR T in DLBCL sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491.jpg%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/elimination-of-rems-program-could-reduce-barriers-to-car-t-in-dlbcl>Elimination of REMS Program Could Reduce Barriers to CAR T in DLBCL/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/targeted-oncology-staff>Targeted Oncology Staff/a>/span>/div>a href/view/elimination-of-rems-program-could-reduce-barriers-to-car-t-in-dlbcl>span classtext-sm text-gray-500>July 30th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy. /p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/cld-201-receives-fda-fast-track-designation-targeting-sarcoma>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altCLD-201 Receives FDA Fast Track Designation Targeting Sarcoma titleCLD-201 Receives FDA Fast Track Designation Targeting Sarcoma srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altCLD-201 Receives FDA Fast Track Designation Targeting Sarcoma titleCLD-201 Receives FDA Fast Track Designation Targeting Sarcoma sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/cld-201-receives-fda-fast-track-designation-targeting-sarcoma>CLD-201 Receives FDA Fast Track Designation Targeting Sarcoma/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/cld-201-receives-fda-fast-track-designation-targeting-sarcoma>span classtext-sm text-gray-500>July 30th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and review process./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/optimizing-cll-sll-therapy-pirtobrutinib-matches-ibrutinib-in-phase-3>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:52.5%>/span>img altOptimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3 titleOptimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3 srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altOptimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3 titleOptimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3 sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/optimizing-cll-sll-therapy-pirtobrutinib-matches-ibrutinib-in-phase-3>Optimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/optimizing-cll-sll-therapy-pirtobrutinib-matches-ibrutinib-in-phase-3>span classtext-sm text-gray-500>July 30th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/rintatolimod-plus-durvalumab-shows-encouraging-early-outcomes-in-metastatic-pancreatic-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altRintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer titleRintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altRintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer titleRintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/rintatolimod-plus-durvalumab-shows-encouraging-early-outcomes-in-metastatic-pancreatic-cancer>Rintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/rintatolimod-plus-durvalumab-shows-encouraging-early-outcomes-in-metastatic-pancreatic-cancer>span classtext-sm text-gray-500>July 30th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic pancreatic cancer patients./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/long-term-follow-up-affirms-ivosidenib-s-sustained-benefit-in-idh1-mutated-aml>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altLong-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML titleLong-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altLong-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML titleLong-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Ff2bc6701ba527babea57a039e5867355c71b1181-480x270.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/long-term-follow-up-affirms-ivosidenib-s-sustained-benefit-in-idh1-mutated-aml>Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/long-term-follow-up-affirms-ivosidenib-s-sustained-benefit-in-idh1-mutated-aml>span classtext-sm text-gray-500>July 30th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, improving patient outcomes significantly./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/breaking-trial-barriers-through-community-inclusive-research>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.27009646302251%>/span>img altBreaking Trial Barriers Through Community-Inclusive Research titleBreaking Trial Barriers Through Community-Inclusive Research srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altBreaking Trial Barriers Through Community-Inclusive Research titleBreaking Trial Barriers Through Community-Inclusive Research sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175.webp%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/breaking-trial-barriers-through-community-inclusive-research>Breaking Trial Barriers Through Community-Inclusive Research/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/nino-balanchivadze-md-facp>Nino Balanchivadze, MD, FACP/a>/span>/div>a href/view/breaking-trial-barriers-through-community-inclusive-research>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Nina Balanchivadze, MD, FACP, discusses how inclusive research begins at the community level by addressing barriers to trial participation./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/fda-review-underway-for-oral-venetoclax-acalabrutinib-combo-in-untreated-cll>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altFDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL titleFDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altFDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL titleFDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/fda-review-underway-for-oral-venetoclax-acalabrutinib-combo-in-untreated-cll>FDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/fda-review-underway-for-oral-venetoclax-acalabrutinib-combo-in-untreated-cll>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in CLL care./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/fda-greenlights-trials-of-novel-adc-and-radiopharmaceutical-in-solid-tumors>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altFDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors titleFDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altFDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors titleFDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/fda-greenlights-trials-of-novel-adc-and-radiopharmaceutical-in-solid-tumors>FDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/jason-m-broderick>Jason M. Broderick/a>/span>/div>a href/view/fda-greenlights-trials-of-novel-adc-and-radiopharmaceutical-in-solid-tumors>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex md:hidden justify-center items-center>/div>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/btx-a51-demonstrates-tolerability-and-manageable-safety-profile-in-patients-with-r-r-aml-mds>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altBTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS titleBTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altBTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS titleBTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F24dcd465d25a34500da55b7948918f713916e486-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/btx-a51-demonstrates-tolerability-and-manageable-safety-profile-in-patients-with-r-r-aml-mds>BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/tony-berberabe-mph>Tony Berberabe, MPH/a>/span>/div>a href/view/btx-a51-demonstrates-tolerability-and-manageable-safety-profile-in-patients-with-r-r-aml-mds>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed or refractory patients with AML or MDS./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/ateganosine-receives-fda-fast-track-designation-for-nsclc>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altAteganosine Receives FDA Fast Track Designation for NSCLC titleAteganosine Receives FDA Fast Track Designation for NSCLC srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altAteganosine Receives FDA Fast Track Designation for NSCLC titleAteganosine Receives FDA Fast Track Designation for NSCLC sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/ateganosine-receives-fda-fast-track-designation-for-nsclc>Ateganosine Receives FDA Fast Track Designation for NSCLC/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/ateganosine-receives-fda-fast-track-designation-for-nsclc>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>MAIA Biotechnology's ateganosine gains FDA fast track status, offering hope for advanced NSCLC patients with limited treatment options./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/long-term-outcomes-bolstered-by-atezolizumab-in-early-stage-triple-negative-breast-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altLong-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer titleLong-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altLong-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer titleLong-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/long-term-outcomes-bolstered-by-atezolizumab-in-early-stage-triple-negative-breast-cancer>Long-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/long-term-outcomes-bolstered-by-atezolizumab-in-early-stage-triple-negative-breast-cancer>span classtext-sm text-gray-500>July 29th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/home-based-mitomycin-instillation-shows-promise-for-low-grade-bladder-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altHome-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer titleHome-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altHome-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer titleHome-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F6e72fc30e74f70c717a633fe2ba63145c1831668-640x360.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/home-based-mitomycin-instillation-shows-promise-for-low-grade-bladder-cancer>Home-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/home-based-mitomycin-instillation-shows-promise-for-low-grade-bladder-cancer>span classtext-sm text-gray-500>July 28th 2025/span>div classmt-2>/div>div classpy-1 text-sm text-gray-500>div classblockText_blockContent__TbCXh>/div>/div>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/metformin-fails-to-improve-survival-in-metastatic-hormone-sensitive-prostate-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altMetformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer titleMetformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altMetformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer titleMetformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa421ea3b3863d973a242702a8cf41c330362014f-480x270.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/metformin-fails-to-improve-survival-in-metastatic-hormone-sensitive-prostate-cancer>Metformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/metformin-fails-to-improve-survival-in-metastatic-hormone-sensitive-prostate-cancer>span classtext-sm text-gray-500>July 28th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/durvalumab-earns-fda-priority-review-for-early-stage-gastric-cancer>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altDurvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer titleDurvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altDurvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer titleDurvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/durvalumab-earns-fda-priority-review-for-early-stage-gastric-cancer>Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/durvalumab-earns-fda-priority-review-for-early-stage-gastric-cancer>span classtext-sm text-gray-500>July 28th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/the-targeted-pulse-july-27>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altThe Targeted Pulse: Key Oncology Updates and Breakthroughs titleThe Targeted Pulse: Key Oncology Updates and Breakthroughs srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altThe Targeted Pulse: Key Oncology Updates and Breakthroughs titleThe Targeted Pulse: Key Oncology Updates and Breakthroughs sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fd15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/the-targeted-pulse-july-27>The Targeted Pulse: Key Oncology Updates and Breakthroughs/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/targeted-oncology-staff>Targeted Oncology Staff/a>/span>/div>a href/view/the-targeted-pulse-july-27>span classtext-sm text-gray-500>July 27th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>This week: FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and TNBC research aims for safer treatments./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/triplet-therapy-shows-promise-for-advanced-tnbc-regardless-of-pd-l1-status>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:56.25%>/span>img altTriplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status titleTriplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altTriplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status titleTriplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2F72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/triplet-therapy-shows-promise-for-advanced-tnbc-regardless-of-pd-l1-status>Triplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/triplet-therapy-shows-promise-for-advanced-tnbc-regardless-of-pd-l1-status>span classtext-sm text-gray-500>July 26th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options./p>/a>div classflex mt-4>/div>/div>/div>/div>div classw-full h-full>div classflex md:hidden justify-center items-center>/div>div classflex mt-4>a classw-full mt-3 md:flex-none md:w-48 href/view/fda-grants-priority-review-to-tab-cel-for-ebv-ptld-after-prior-therapies>div class>span stylebox-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;padding-top:100%>/span>img altFDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies titleFDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgresponsive classshrink-0 styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img altFDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies titleFDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies sizes100vw srcSet/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w640&q75 640w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w750&q75 750w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w828&q75 828w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1080&q75 1080w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1200&q75 1200w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w1920&q75 1920w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w2048&q75 2048w, /_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 3840w src/_next/image?urlhttps%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Ftargetedonc%2Fa255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200.png%3Ffit%3Dcrop%26auto%3Dformat&w3840&q75 decodingasync data-nimgresponsive styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% classshrink-0 loadinglazy/>/noscript>/span>/div>/a>div classw-200% md:w-auto flex-auto p-2 ml-2>p classfont-bold>a class href/view/fda-grants-priority-review-to-tab-cel-for-ebv-ptld-after-prior-therapies>FDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies/a>/p>div>span classtext-md >span classmr-1 italic>By /span>a classmr-1 text-sky-800 hover:text-primary href/authors/sabrina-serani>Sabrina Serani/a>/span>/div>a href/view/fda-grants-priority-review-to-tab-cel-for-ebv-ptld-after-prior-therapies>span classtext-sm text-gray-500>July 25th 2025/span>div classmt-2>/div>p classmt-4 text-gray-800>FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options./p>/a>div classflex mt-4>/div>/div>/div>/div>/div>div classtext-center w-full pt-4 text-2xl font-bold pb-24>a classtext-lg hover:text-gray-400 hover:underline href/news>See All News !-- -->>/a>/div>/div>/div>div classflex-none w-300px z-9999 relative hidden md:block>div styletop:70px;margin-top:44px classsticky custom-spacing>/div>/div>/div>noscript>iframe srchttps://www.googletagmanager.com/ns.html?idGTM-KKCZB52 height0 width0 styledisplay:none;visibility:hidden>/iframe>/noscript>div idfooterOuterWrap classw-full bg-primary flex flex-col items-center justify-center customClassHideFooter mt-10>div classcontainer w-1340px>div idfooterInnerWrap classbg-primary w-full py-12>div classpy-4 pl-4 flex flex-row items-center>div classflex flex-row flex-wrap w-55% h-full>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_self href/about>About Us/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_self href/advertise>Advertise/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_self href/contactus>Contact Us/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank hrefhttps://www.curetoday.com>CureToday.com/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank hrefhttps://www.cancernetwork.com>CancerNetwork.com/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank hrefhttps://www.onclive.com>OncLive.com/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank hrefhttps://www.oncnursingnews.com/>OncNursingNews.com/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank hrefhttps://www.mjhlifesciences.com/ccpa?domainwww.targetedonc.com>Do Not Sell My Information/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank href/privacy>Privacy/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_blank href/terms>Terms & Conditions/a>/div>div classw-33% p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline>a classtext-md target_self href/editorial-board>Editorial Board/a>/div>/div>div classw-45% flex flex-row>div classw-1px bg-footer-vertical-rule>/div>div classtext-center flex w-50% flex-col gap-4 px-8 text-footer-text-color>div classpy-2 text-xl>Contact Info/div>div classmx-auto>div classflex flex-row gap-4 mb-4>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 24 24 classtext-footer-icon-color font-size30 stylemargin-top:0.2rem height1em width1em xmlnshttp://www.w3.org/2000/svg>path fillnone dM0 0h24v24H0z>/path>path dM12 2C8.13 2 5 5.13 5 9c0 1.74.5 3.37 1.41 4.84.95 1.54 2.2 2.86 3.16 4.4.47.75.81 1.45 1.17 2.26.26.55.47 1.5 1.26 1.5s1-.95 1.25-1.5c.37-.81.7-1.51 1.17-2.26.96-1.53 2.21-2.85 3.16-4.4C18.5 12.37 19 10.74 19 9c0-3.87-3.13-7-7-7zm0 9.75a2.5 2.5 0 010-5 2.5 2.5 0 010 5z>/path>/svg>p classtext-left text-sm>2 Commerce Drive br/>Cranbury, NJ 08512/p>/div>div classflex flex-row gap-4 mb-4>svg strokecurrentColor fillcurrentColor stroke-width0 viewBox0 0 16 16 classtext-footer-icon-color ml-2 font-size25 height1em width1em xmlnshttp://www.w3.org/2000/svg>path fill-ruleevenodd dM1.885.511a1.745 1.745 0 0 1 2.61.163L6.29 2.98c.329.423.445.974.315 1.494l-.547 2.19a.678.678 0 0 0 .178.643l2.457 2.457a.678.678 0 0 0 .644.178l2.189-.547a1.745 1.745 0 0 1 1.494.315l2.306 1.794c.829.645.905 1.87.163 2.611l-1.034 1.034c-.74.74-1.846 1.065-2.877.702a18.634 18.634 0 0 1-7.01-4.42 18.634 18.634 0 0 1-4.42-7.009c-.362-1.03-.037-2.137.703-2.877L1.885.511z>/path>/svg>p classtext-sm>a hreftel:609-716-7777>609-716-7777/a>/p>/div>/div>/div>div classw-1px bg-footer-vertical-rule>/div>div classflex flex-col gap-4 items-center justify-center stylemargin:0 auto>span stylebox-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%>span stylebox-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%>img styledisplay:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0 alt aria-hiddentrue srcdata:image/svg+xml,%3csvg%20xmlns%27http://www.w3.org/2000/svg%27%20version%271.1%27%20width%27200%27%20height%2733%27/%3e/>/span>img alt srcdata:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%/>noscript>img alt srcSet/_next/image?url%2Fan_mjhls_brand_ko.png&w256&q75 1x, /_next/image?url%2Fan_mjhls_brand_ko.png&w640&q75 2x src/_next/image?url%2Fan_mjhls_brand_ko.png&w640&q75 decodingasync data-nimgintrinsic styleposition:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100% loadinglazy/>/noscript>/span>div classflex flex-wrap self-start pl-2>a hrefhttps://www.facebook.com/TargetedOnc/ classsocial-icon mx-0.5 mb-1 target_blank relnoopener noreferrer styledisplay:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle aria-labelfacebook>span classsocial-container styleposition:absolute;top:0;left:0;width:100%;height:100%>svg roleimg aria-labelfacebook social icon classsocial-svg viewBox0 0 64 64 styleposition:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd>g classsocial-svg-icon styletransition:fill 170ms ease-in-out;fill:white>path dM0,0H64V64H0ZM0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z>/path>/g>g classsocial-svg-mask styletransition:fill 170ms ease-in-out;fill:#3b5998>path dM0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z>/path>/g>/svg>/span>/a>a hrefhttps://www.linkedin.com/company/targetedonc classsocial-icon mx-0.5 mb-1 target_blank relnoopener noreferrer styledisplay:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle aria-labellinkedin>span classsocial-container styleposition:absolute;top:0;left:0;width:100%;height:100%>svg roleimg aria-labellinkedin social icon classsocial-svg viewBox0 0 64 64 styleposition:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd>g classsocial-svg-icon styletransition:fill 170ms ease-in-out;fill:white>path dM0,0H64V64H0ZM0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z>/path>/g>g classsocial-svg-mask styletransition:fill 170ms ease-in-out;fill:#007fb1>path dM0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z>/path>/g>/svg>/span>/a>a hrefhttps://twitter.com/TargetedOnc classsocial-icon mx-0.5 mb-1 target_blank relnoopener noreferrer styledisplay:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle aria-labelx>span classsocial-container styleposition:absolute;top:0;left:0;width:100%;height:100%>svg roleimg aria-labelx social icon classsocial-svg viewBox0 0 64 64 styleposition:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd>g classsocial-svg-icon styletransition:fill 170ms ease-in-out;fill:white>path dM0,0H64V64H0ZM0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z>/path>/g>g classsocial-svg-mask styletransition:fill 170ms ease-in-out;fill:#000000>path dM0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z>/path>/g>/svg>/span>/a>a hrefhttps://www.youtube.com/user/TargetedHC classsocial-icon mx-0.5 mb-1 target_blank relnoopener noreferrer styledisplay:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle aria-labelyoutube>span classsocial-container styleposition:absolute;top:0;left:0;width:100%;height:100%>svg roleimg aria-labelyoutube social icon classsocial-svg viewBox0 0 64 64 styleposition:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd>g classsocial-svg-icon styletransition:fill 170ms ease-in-out;fill:white>path dM0,0H64V64H0ZM0 0v64h64V0zm47 33.1c0 2.4-.3 4.9-.3 4.9s-.3 2.1-1.2 3c-1.1 1.2-2.4 1.2-3 1.3-4.2.2-10.5.3-10.5.3s-7.8-.1-10.2-.3c-.7-.1-2.2-.1-3.3-1.3-.9-.9-1.2-3-1.2-3s-.3-2.4-.3-4.9v-2.3c0-2.4.3-4.9.3-4.9s.3-2.1 1.2-3c1.1-1.2 2.4-1.2 3-1.3 4.2-.3 10.5-.3 10.5-.3s6.3 0 10.5.3c.6.1 1.9.1 3 1.3.9.9 1.2 3 1.2 3s.3 2.4.3 4.9zm-18.1 2.8 8.1-4.2-8.1-4.2z>/path>/g>g classsocial-svg-mask styletransition:fill 170ms ease-in-out;fill:#ff3333>path dM0 0v64h64V0zm47 33.1c0 2.4-.3 4.9-.3 4.9s-.3 2.1-1.2 3c-1.1 1.2-2.4 1.2-3 1.3-4.2.2-10.5.3-10.5.3s-7.8-.1-10.2-.3c-.7-.1-2.2-.1-3.3-1.3-.9-.9-1.2-3-1.2-3s-.3-2.4-.3-4.9v-2.3c0-2.4.3-4.9.3-4.9s.3-2.1 1.2-3c1.1-1.2 2.4-1.2 3-1.3 4.2-.3 10.5-.3 10.5-.3s6.3 0 10.5.3c.6.1 1.9.1 3 1.3.9.9 1.2 3 1.2 3s.3 2.4.3 4.9zm-18.1 2.8 8.1-4.2-8.1-4.2z>/path>/g>/svg>/span>/a>a hrefhttps://www.instagram.com/targetedoncology/ classsocial-icon mx-0.5 mb-1 target_blank relnoopener noreferrer styledisplay:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle aria-labelinstagram>span classsocial-container styleposition:absolute;top:0;left:0;width:100%;height:100%>svg roleimg aria-labelinstagram social icon classsocial-svg viewBox0 0 64 64 styleposition:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd>g classsocial-svg-icon styletransition:fill 170ms ease-in-out;fill:white>path dM0,0H64V64H0ZM0 0v64h64V0zm39.88 25.89c.98 0 1.77-.79 1.77-1.77s-.79-1.77-1.77-1.77-1.77.79-1.77 1.77.79 1.77 1.77 1.77M32 24.42c-4.18 0-7.58 3.39-7.58 7.58s3.4 7.58 7.58 7.58 7.58-3.4 7.58-7.58-3.4-7.58-7.58-7.58m0 12.5c-2.72 0-4.92-2.2-4.92-4.92s2.2-4.92 4.92-4.92 4.92 2.2 4.92 4.92-2.2 4.92-4.92 4.92m0-17.02c3.94 0 4.41.02 5.96.09 1.45.06 2.23.3 2.75.51.69.27 1.18.58 1.7 1.1.51.52.83 1.01 1.1 1.7.2.52.44 1.3.51 2.74.07 1.56.09 2.02.09 5.97 0 3.94-.02 4.4-.09 5.96-.07 1.44-.31 2.22-.51 2.74-.27.69-.59 1.19-1.1 1.7-.52.52-1.01.84-1.7 1.1-.52.2-1.3.45-2.75.51-1.55.07-2.02.09-5.96.09s-4.41-.02-5.96-.09c-1.45-.06-2.23-.3-2.75-.51-.69-.27-1.18-.58-1.7-1.1-.51-.51-.83-1.01-1.1-1.7-.2-.52-.44-1.3-.51-2.74-.07-1.56-.09-2.02-.09-5.96 0-3.95.02-4.41.09-5.97.07-1.44.31-2.22.51-2.74.27-.69.59-1.18 1.1-1.7.52-.52 1.01-.84 1.7-1.1.52-.2 1.3-.45 2.75-.51 1.55-.08 2.02-.09 5.96-.09m0-2.66c-4.01 0-4.51.02-6.09.09-1.57.07-2.64.32-3.58.68-.97.38-1.79.89-2.61 1.71s-1.33 1.65-1.71 2.61c-.36.94-.61 2.01-.68 3.59-.07 1.57-.09 2.07-.09 6.08s.02 4.51.09 6.09c.07 1.57.32 2.64.68 3.58.38.98.89 1.8 1.71 2.62s1.65 1.32 2.61 1.7c.94.37 2.01.62 3.59.69 1.57.07 2.07.09 6.09.09 4.01 0 4.51-.02 6.08-.09s2.65-.32 3.59-.69c.97-.37 1.79-.88 2.61-1.7s1.33-1.65 1.71-2.62c.36-.93.61-2.01.68-3.58.07-1.58.09-2.08.09-6.09s-.02-4.51-.09-6.09c-.07-1.57-.32-2.64-.68-3.58-.38-.98-.89-1.8-1.71-2.62a7.3 7.3 0 0 0-2.61-1.7c-.94-.37-2.01-.62-3.59-.69-1.58-.06-2.08-.08-6.09-.08>/path>/g>g classsocial-svg-mask styletransition:fill 170ms ease-in-out;fill:#e94475>path dM0 0v64h64V0zm39.88 25.89c.98 0 1.77-.79 1.77-1.77s-.79-1.77-1.77-1.77-1.77.79-1.77 1.77.79 1.77 1.77 1.77M32 24.42c-4.18 0-7.58 3.39-7.58 7.58s3.4 7.58 7.58 7.58 7.58-3.4 7.58-7.58-3.4-7.58-7.58-7.58m0 12.5c-2.72 0-4.92-2.2-4.92-4.92s2.2-4.92 4.92-4.92 4.92 2.2 4.92 4.92-2.2 4.92-4.92 4.92m0-17.02c3.94 0 4.41.02 5.96.09 1.45.06 2.23.3 2.75.51.69.27 1.18.58 1.7 1.1.51.52.83 1.01 1.1 1.7.2.52.44 1.3.51 2.74.07 1.56.09 2.02.09 5.97 0 3.94-.02 4.4-.09 5.96-.07 1.44-.31 2.22-.51 2.74-.27.69-.59 1.19-1.1 1.7-.52.52-1.01.84-1.7 1.1-.52.2-1.3.45-2.75.51-1.55.07-2.02.09-5.96.09s-4.41-.02-5.96-.09c-1.45-.06-2.23-.3-2.75-.51-.69-.27-1.18-.58-1.7-1.1-.51-.51-.83-1.01-1.1-1.7-.2-.52-.44-1.3-.51-2.74-.07-1.56-.09-2.02-.09-5.96 0-3.95.02-4.41.09-5.97.07-1.44.31-2.22.51-2.74.27-.69.59-1.18 1.1-1.7.52-.52 1.01-.84 1.7-1.1.52-.2 1.3-.45 2.75-.51 1.55-.08 2.02-.09 5.96-.09m0-2.66c-4.01 0-4.51.02-6.09.09-1.57.07-2.64.32-3.58.68-.97.38-1.79.89-2.61 1.71s-1.33 1.65-1.71 2.61c-.36.94-.61 2.01-.68 3.59-.07 1.57-.09 2.07-.09 6.08s.02 4.51.09 6.09c.07 1.57.32 2.64.68 3.58.38.98.89 1.8 1.71 2.62s1.65 1.32 2.61 1.7c.94.37 2.01.62 3.59.69 1.57.07 2.07.09 6.09.09 4.01 0 4.51-.02 6.08-.09s2.65-.32 3.59-.69c.97-.37 1.79-.88 2.61-1.7s1.33-1.65 1.71-2.62c.36-.93.61-2.01.68-3.58.07-1.58.09-2.08.09-6.09s-.02-4.51-.09-6.09c-.07-1.57-.32-2.64-.68-3.58-.38-.98-.89-1.8-1.71-2.62a7.3 7.3 0 0 0-2.61-1.7c-.94-.37-2.01-.62-3.59-.69-1.58-.06-2.08-.08-6.09-.08>/path>/g>/svg>/span>/a>/div>/div>/div>/div>/div>/div>div classw-full bg-secondary flex justify-center>div classbg-secondary w-85% text-subfooter-text-color text-sm font-bold>div classflex flex-col gap-8 md:flex-row justify-between p-4 md:py-4 md:px-12>div>© !-- -->2025!-- --> MJH Life Sciences br/> br/> All rights reserved./div>div classflex flex-column stylegap:2rem;align-items:center>/div>/div>/div>/div>/div>/div>/div>script id__NEXT_DATA__ typeapplication/json>{props:{pageProps:{pageProps:{},cache:{main_menu:{_createdAt:2020-02-17T15:09:30Z,_id:942a15ca-4758-408f-8e65-30cc037b8961,_rev:RC3djkanmLdUHDDaXTE7TR,_type:mainNavigation,_updatedAt:2023-01-26T19:22:32Z,is_active:true,name:NEWS,navParent:null,sortOrder:1,subQuery:{_createdAt:2021-11-19T17:23:12Z,_id:0bcbdfad-30c2-4a31-afa4-b58972dd8c15,_rev:dIUASYbXgdcZUlzqe6EHbm,_type:mainNavigation,_updatedAt:2025-03-19T20:04:19Z,children:,is_active:true,name:Special Reports,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},sortOrder:3,url:/news/special-reports},{_createdAt:2021-11-19T19:25:21Z,_id:7651e644-d8b3-4c98-a7c9-e8ddf8ffee09,_rev:ml0t2Atc7eI5N7MRwXpjXf,_type:mainNavigation,_updatedAt:2021-11-19T19:25:21Z,children:,is_active:true,name:All News,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},url:/news},{_createdAt:2023-05-05T14:40:20Z,_id:c9ee7df6-21b7-4933-9c39-8c5e5c0ba5d6,_rev:l98Fas1mWH34jFsgcHK5od,_type:mainNavigation,_updatedAt:2023-05-08T19:19:21Z,children:,is_active:true,name:FDA Briefs,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},url:/fda-briefs},{_createdAt:2023-05-05T14:33:26Z,_id:ad4dee8c-922d-492f-a9ca-a457bc65187d,_rev:JMINlicoLdaQWqVd4VYdB4,_type:mainNavigation,_updatedAt:2023-05-05T15:12:11Z,children:,is_active:true,name:Oncology Icons,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},url:/oncology-icons},{_createdAt:2024-10-28T13:07:05Z,_id:2b165a25-fc63-421e-ac9f-a9f5ef8b9b4e,_rev:krXXfJdIGzkhUe12uGeuzq,_type:mainNavigation,_updatedAt:2024-10-28T13:07:21Z,children:,is_active:true,name:The Targeted Pulse,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},url:/the-targeted-pulse},{_createdAt:2023-05-04T15:53:17Z,_id:e7d5cb7f-84ee-44ed-bc56-b2ac8445d70b,_rev:aw7kHvW9cFGHKhSIbN9SPW,_type:mainNavigation,_updatedAt:2025-03-19T20:03:50Z,children:,is_active:true,name:Voices from the Field,navParent:{_ref:942a15ca-4758-408f-8e65-30cc037b8961,_type:reference},url:/news/voices-from-the-field},url:/news},{_createdAt:2020-02-17T15:34:51Z,_id:166c6c17-d836-46a0-a5df-6beebb32bdc2,_rev:vyEOe6El8eq2lqoxxoZaj6,_type:mainNavigation,_updatedAt:2023-02-01T21:03:13Z,is_active:true,name:CONFERENCES,navParent:null,sortOrder:2,subQuery:{_createdAt:2020-04-21T19:17:27Z,_id:ee0a0fa3-3391-484e-8f3e-33053492e988,_rev:qfZL75w3CFNMVci4ajcs7M,_type:mainNavigation,_updatedAt:2020-08-13T17:12:50Z,children:,is_active:true,name:Conference Coverage,navParent:{_ref:166c6c17-d836-46a0-a5df-6beebb32bdc2,_type:reference},sortOrder:1,url:/latest-conference},{_createdAt:2020-04-21T19:17:30Z,_id:df33750f-acb5-455b-bab5-60b2f7d5eee6,_rev:k1HuCfztD5tUO5oNRJ0zGk,_type:mainNavigation,_updatedAt:2020-08-13T17:12:54Z,children:,is_active:true,name:Conference Listing,navParent:{_ref:166c6c17-d836-46a0-a5df-6beebb32bdc2,_type:reference},sortOrder:2,url:/conference},{_createdAt:2023-07-06T16:10:01Z,_id:b7b78825-d4c2-4c97-a4e4-e3146d514512,_rev:oNLk066EhGOYfXx5VQCxA9,_type:mainNavigation,_updatedAt:2023-07-06T17:00:51Z,children:,is_active:true,name:Data Dialogue with the Oncology Brothers,navParent:{_ref:166c6c17-d836-46a0-a5df-6beebb32bdc2,_type:reference},sortOrder:3,url:/data-dialogue-with-the-oncology-brothers},url:/conference},{_createdAt:2020-02-17T15:28:51Z,_id:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_rev:DQCQmysqcSI8ZLPSLPRk53,_type:mainNavigation,_updatedAt:2023-01-26T19:22:24Z,blank:false,is_active:true,name:MEDIA,navParent:null,sortOrder:3,subQuery:{_createdAt:2020-02-18T14:11:48Z,_id:23c122e9-aafd-4fc3-ba95-e4ebf33ad1d5,_rev:DQCQmysqcSI8ZLPSLPNBBm,_type:mainNavigation,_updatedAt:2023-01-26T18:17:42Z,children:,is_active:true,name:All Videos,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/videos},{_createdAt:2020-02-17T15:30:09Z,_id:043db81c-951d-4dfb-905d-2141fbee8146,_rev:5EFAHJWBnybshQjXMxhgMG,_type:mainNavigation,_updatedAt:2020-02-18T14:14:17Z,children:,is_active:true,name:Case-Based Peer Perspectives,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/case-based-peer-perspectives},{_createdAt:2020-02-17T15:34:15Z,_id:3089d1e9-b978-4bcd-8ca4-677c3a88c76f,_rev:pTTEsYMvrHYizt5rDmvSNh,_type:mainNavigation,_updatedAt:2025-03-07T19:24:40Z,children:,is_active:true,name:Evolving Paradigms in Oncology,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/evolving-paradigms-in-oncology},{_createdAt:2020-02-17T15:31:13Z,_id:ff80d109-2836-4ce5-bc96-a60513f62167,_rev:7Ay9LXdD69pFsviUTfS6aE,_type:mainNavigation,_updatedAt:2020-03-11T13:51:00Z,children:,is_active:true,name:Expert Perspective Virtual Tumor Board,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/expert-perspective-tumor-board},{_createdAt:2020-02-17T15:32:23Z,_id:bc55af3d-b530-4edb-a0c9-5bfdf5509cda,_rev:msyEeP9pzbpEnxXiS6ftMV,_type:mainNavigation,_updatedAt:2020-02-18T14:12:19Z,children:,is_active:true,name:Interviews,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/interviews},{_createdAt:2020-02-17T15:33:04Z,_id:127663c6-810e-4524-a5e7-d4de3b4f68a2,_rev:k08aZDJD3y2e2XTRCNIiTh,_type:mainNavigation,_updatedAt:2020-02-18T14:13:01Z,children:,is_active:true,name:Investigator Perspectives,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/investigator-perspectives},{_createdAt:2020-06-24T17:10:28Z,_id:6e2a7af4-9aaf-45fa-bbff-833dc1350b90,_rev:DQCQmysqcSI8ZLPSLemG0M,_type:mainNavigation,_updatedAt:2023-02-03T20:11:43Z,blank:true,children:,is_active:true,name:Medical World News,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:https://www.medicalworldnews.com/},{_createdAt:2025-04-15T15:16:32Z,_id:5c72244b-012b-4703-98bb-d38108d6b1ba,_rev:t0rkT0chPXSLTj95v0iem8,_type:mainNavigation,_updatedAt:2025-04-15T15:16:55Z,children:,is_active:true,name:Personalized Medicine,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/personalized-medicine-in},{_createdAt:2023-05-18T17:16:36Z,_id:38d005ca-1a46-4adc-a19d-5ebc2154f3c6,_rev:S0Xq8wRLexjiymiiMOCOzl,_type:mainNavigation,_updatedAt:2023-05-18T17:16:51Z,blank:true,children:,is_active:true,name:Pivotal Practice Views with the Oncology Brothers,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/pivotal-practice-views-with-the-oncology-brothers},{_createdAt:2020-06-16T15:24:20Z,_id:7a619ba8-1a1e-47e6-b23a-58438f4901dc,_rev:TP2Dz46QPIXKugst49hCMn,_type:mainNavigation,_updatedAt:2020-06-16T15:24:20Z,children:,is_active:true,name:Podcasts,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/podcasts},{_createdAt:2024-05-10T19:03:28Z,_id:4fb05d37-8ff0-4143-ad70-7e3fe4f567d0,_rev:XOeleduglaxOTTVtBnzkCF,_type:mainNavigation,_updatedAt:2024-05-10T19:03:49Z,blank:true,children:,is_active:true,name:Speaking Out,navParent:{_ref:82c27fd1-f196-4ce7-b2d2-447592ab32a6,_type:reference},url:/speaking-out},url:/videos},{_createdAt:2020-02-17T15:36:19Z,_id:729768de-1250-449b-ad75-99bee309200c,_rev:O5pHPd1R4jYUjZOwPCrIx8,_type:mainNavigation,_updatedAt:2023-01-26T19:22:58Z,is_active:true,name:PUBLICATIONS,navParent:null,sortOrder:4,subQuery:{_createdAt:2020-02-18T14:15:19Z,_id:5f616c58-2592-4551-a923-a4dc19e98e76,_rev:dHI21CKQopRHXKfH8LL7v7,_type:mainNavigation,_updatedAt:2020-03-11T13:51:19Z,children:,is_active:true,name:All Publications,navParent:{_ref:729768de-1250-449b-ad75-99bee309200c,_type:reference},url:/publications},{_createdAt:2020-02-17T15:46:57Z,_id:77f9a375-0b80-4962-a782-a60cda69795f,_rev:VtWbjFCFsbe79VjDrOJ1Yl,_type:mainNavigation,_updatedAt:2020-02-18T20:16:57Z,children:,is_active:true,name:Evolving Paradigms,navParent:{_ref:729768de-1250-449b-ad75-99bee309200c,_type:reference},url:/publications/evolving-paradigms},{_createdAt:2020-07-24T20:16:07Z,_id:29127747-769c-4593-9448-372eaa25f6e1,_rev:Xg78xFKVkbsFs7BDUyFWjE,_type:mainNavigation,_updatedAt:2023-06-13T18:13:55Z,children:,is_active:true,name:Peers \u0026 Perspectives in Oncology,navParent:{_ref:729768de-1250-449b-ad75-99bee309200c,_type:reference},url:/publications/peers-perspectives-in-oncology},{_createdAt:2020-02-17T15:48:37Z,_id:ca3b7426-8a29-4f06-bbbe-eacc8364b7f3,_rev:8iSM7FvbiCb87r4WMlc9tB,_type:mainNavigation,_updatedAt:2020-02-18T14:16:04Z,children:,is_active:true,name:Targeted Therapies in Oncology,navParent:{_ref:729768de-1250-449b-ad75-99bee309200c,_type:reference},url:/publications/targeted-therapy-news},url:/publications},{_createdAt:2021-09-27T14:22:17Z,_id:43a071ff-cf82-4def-bfe8-8bc4d8859d02,_rev:Pco71BhnOp9iD3usLyTdsV,_type:mainNavigation,_updatedAt:2024-06-04T20:20:01Z,is_active:true,name:CASE-BASED ROUNDTABLE,navParent:null,sortOrder:5,subQuery:,url:/case-based-roundtable-series},{_createdAt:2020-02-24T21:34:47Z,_id:5a5578ce-fa81-4a9c-91f7-8ffb3694f506,_rev:ZARUrvtActr8bNkcuMbEQ9,_type:mainNavigation,_updatedAt:2024-06-04T20:04:58Z,is_active:true,name:PARTNERS,navParent:null,sortOrder:6,subQuery:,url:/partners},{_createdAt:2020-10-07T20:07:38Z,_id:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_rev:YCgKmZHkZ9BdJmd5Z2YjIL,_type:mainNavigation,_updatedAt:2024-06-04T20:04:38Z,is_active:true,name:RESOURCES,navParent:null,sortOrder:7,subQuery:{_createdAt:2020-03-10T21:28:17Z,_id:0897671e-e29f-4612-b5cc-b68d9a415fa1,_rev:YCgKmZHkZ9BdJmd5Z2Yiuy,_type:mainNavigation,_updatedAt:2024-06-04T20:03:14Z,children:,is_active:true,name:CME/CE,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/continuing-education},{_createdAt:2021-07-15T21:08:13Z,_id:c1486c28-57f0-431a-84f9-62fc36014b7a,_rev:MMii0XioXyCM6kHQMGNScu,_type:mainNavigation,_updatedAt:2021-10-04T15:22:50Z,children:,is_active:true,name:Clinical Trials,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/clinical-trials},{_createdAt:2025-01-16T16:33:10Z,_id:5db155b9-3cd3-489d-8ebc-d4402b750879,_rev:rnb16y4e0BKBgYGF37evwb,_type:mainNavigation,_updatedAt:2025-01-16T16:33:30Z,children:,is_active:true,name:Events,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/events},{_createdAt:2021-04-27T16:41:37Z,_id:a1283f39-0a97-49a3-a5e9-2a92687eb550,_rev:az405sdEGiNXkcQPik3pcw,_type:mainNavigation,_updatedAt:2021-04-27T16:41:37Z,children:,is_active:true,name:Precision Medicine Perspectives,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/precision-medicine-perspectives},{_createdAt:2020-02-17T19:21:20Z,_id:e1aadb87-f7e9-4c18-9708-7e4dd57ec0d8,_rev:Pf0H36I4kozHvdWXsf1TX1,_type:mainNavigation,_updatedAt:2021-01-28T22:19:16Z,children:,is_active:true,name:Press Releases,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/press-releases},{_createdAt:2022-10-03T17:28:20Z,_id:4bad25f2-3c2b-4b0a-96d7-0cc64266185f,_rev:mvtohJ2t1KUwt9kTKqyuBC,_type:mainNavigation,_updatedAt:2022-10-03T17:28:20Z,children:,is_active:true,name:Sponsored Content,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/sponsored},{_createdAt:2021-06-03T20:58:17Z,_id:685cb0f8-ee60-44b9-a85e-e1f52b96b4a4,_rev:W3Hv8ENQcTSYNKIrv2jAyy,_type:mainNavigation,_updatedAt:2021-06-03T20:58:40Z,children:,is_active:true,name:Treatment Resources,navParent:{_ref:f8307a8f-fde5-4c9e-b2c8-c595fcc2c782,_type:reference},url:/treatment-resources}},{_createdAt:2020-06-10T16:40:35Z,_id:5b7219a2-3b69-4bd3-8d8a-d147584a8d8b,_rev:ZARUrvtActr8bNkcuMbEAN,_type:mainNavigation,_updatedAt:2024-06-04T20:04:51Z,blank:true,is_active:true,name:SUBSCRIBE,navParent:null,sortOrder:8,subQuery:,url:https://one.targetedonc.com/subscribe},sub_menu:{_createdAt:2020-04-20T18:23:53Z,_id:7e0387b0-d390-4262-91fb-1f59ba3fc305,_rev:V3uHY7tQ1rZv1zRCpb7Enc,_type:subNavigation,_updatedAt:2020-04-28T01:24:07Z,is_active:true,name:Featured Clinical Focus,navParent:null,sortOrder:1,subQuery:{_createdAt:2021-01-05T18:29:53Z,_id:875ac6bc-cc65-40d4-baaa-4fa176f8d5ae,_rev:QmO70L3Tk4R1Vn3dkCO3dJ,_type:subNavigation,_updatedAt:2021-01-05T18:30:14Z,children:,is_active:true,name:AML,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/aml},{_createdAt:2021-05-25T18:51:00Z,_id:0dc26c93-1357-4426-ae0f-f79921c3d3cb,_rev:fqu5PhfWUe5geBzCarXYxd,_type:subNavigation,_updatedAt:2021-05-25T18:51:15Z,children:,is_active:true,name:BTK Inhibitors: In-Focus,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/precision-medicine-perspectives/btk-inhibitors-in-focus},{_createdAt:2021-03-15T18:57:52Z,_id:9907d3a4-601f-41f1-821c-b16764f08825,_rev:aR8FoG3wTLjmNfPDCkFKaO,_type:subNavigation,_updatedAt:2022-01-31T15:40:02Z,children:,is_active:true,name:Biomarker-Driven Lung Cancer,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/biomarker-lung-cancer},{_createdAt:2021-01-05T18:31:46Z,_id:36c0909e-4165-4c63-8e9a-66b4f1311188,_rev:aR8FoG3wTLjmNfPDCkF9dl,_type:subNavigation,_updatedAt:2022-01-31T15:38:42Z,children:,is_active:true,name:Bone Marrow \u0026 SCT,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/bone-marrow-and-sct},{_createdAt:2020-04-21T14:44:16Z,_id:a5f555f4-7947-4f2e-840a-192d73e090e2,_rev:RqNOjk541boYBSZIpiz6Yz,_type:subNavigation,_updatedAt:2020-04-21T14:44:16Z,children:,is_active:true,name:CAR T-Cell Therapy,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/car-t-cell-therapy},{_createdAt:2020-04-21T14:44:37Z,_id:9305458e-73af-4916-9392-961196b9c5c8,_rev:aDHVH7iwF1VnyMBXAI0uS9,_type:subNavigation,_updatedAt:2020-04-21T14:44:37Z,children:,is_active:true,name:Chronic Lymphocytic Leukemia,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/cll},{_createdAt:2021-05-25T18:50:04Z,_id:1b58b498-ceca-44e7-8311-7b6db27c4ec8,_rev:D3A9by6kaubL5OqaE4Bsyk,_type:subNavigation,_updatedAt:2022-01-31T15:37:52Z,children:,is_active:true,name:EGFR-Positive Lung Cancer,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/egfr-positive-lungcancer},{_createdAt:2021-10-04T20:51:40Z,_id:254d6921-e9a5-46f9-8bb9-12723870ed6c,_rev:9UXag5YnB6rNSPRzptKZ8G,_type:subNavigation,_updatedAt:2021-10-04T21:12:11Z,children:,is_active:true,name:Endometrial Cancer,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/endometrial-cancer},{_createdAt:2020-04-21T14:44:59Z,_id:2843eda2-7e91-458d-8787-73a7a7c54bc7,_rev:tygLEjhvvRqFAzmHjEKIcn,_type:subNavigation,_updatedAt:2021-07-29T19:54:42Z,children:,is_active:true,name:Follicular Lymphoma,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/follicularlymphoma},{_createdAt:2020-04-20T18:24:06Z,_id:3f9e0de1-5065-4b69-bdc7-c3e566cb9458,_rev:RqNOjk541boYBSZIphdrjB,_type:subNavigation,_updatedAt:2020-04-20T18:24:06Z,children:,is_active:true,name:HCC,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/hcc},{_createdAt:2020-04-21T14:46:02Z,_id:acb3f175-84e2-412a-bc22-5fb89be3e58b,_rev:GTG2tHbJ6moVt8yIbeIzir,_type:subNavigation,_updatedAt:2020-04-21T14:47:37Z,children:,is_active:true,name:Lung Cancer,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/lung},{_createdAt:2020-04-21T14:49:59Z,_id:5edc9597-3956-4539-ad6d-1539bf9018c4,_rev:XY6CFg6hVjzh7pBAH0OrbC,_type:subNavigation,_updatedAt:2020-04-21T14:49:59Z,children:,is_active:true,name:MPNs,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/mpn},{_createdAt:2020-04-21T14:49:37Z,_id:e588a832-7edb-4d35-8d1c-ff1a498844f4,_rev:lauLgb45L3iUAP8GZQZY5G,_type:subNavigation,_updatedAt:2020-04-21T14:49:37Z,children:,is_active:true,name:Mantle Cell Lymphoma,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/mcl},{_createdAt:2020-04-21T14:50:15Z,_id:e6d05709-a276-49ed-88f3-7b851bae4106,_rev:l1sFAT6EWug9ncSv8wS8wn,_type:subNavigation,_updatedAt:2020-04-21T14:50:15Z,children:,is_active:true,name:Multiple Myeloma,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/multiple-myeloma-rc},{_createdAt:2020-05-18T21:02:02Z,_id:1f35acff-41d3-4ebc-839d-b2ae77bb0a7b,_rev:6V9a5LVb8b872nynJGdbUc,_type:subNavigation,_updatedAt:2020-05-18T21:02:02Z,children:,is_active:true,name:Renal Cell Carcinoma,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/rcc},{_createdAt:2020-04-21T15:25:04Z,_id:94b2f20c-8174-4a44-afa0-06bd26912ccd,_rev:aR8FoG3wTLjmNfPDCkFF2Y,_type:subNavigation,_updatedAt:2022-01-31T15:39:25Z,children:,is_active:true,name:Small Cell Lung Cancer,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/small-cell-lung-cancer},{_createdAt:2020-05-18T21:02:59Z,_id:f35142be-8676-4d2e-98f7-fb54063fb3c4,_rev:r3AF2dtWG3TDYH1ZEVDJhy,_type:subNavigation,_updatedAt:2020-05-18T21:02:59Z,children:,is_active:true,name:Thyroid Cancers,navParent:{_ref:7e0387b0-d390-4262-91fb-1f59ba3fc305,_type:reference},url:/clinical/thyroid}},{_createdAt:2020-02-17T15:53:15Z,_id:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_rev:RqNOjk541boYBSZIplYHph,_type:subNavigation,_updatedAt:2020-04-22T20:21:32Z,is_active:true,name:Clinical Focus,navParent:null,sortOrder:2,subQuery:{_createdAt:2020-02-17T15:55:13Z,_id:f64fe38a-4391-4810-a3f0-6bc4af6128f6,_rev:NgOVPrTlffdjZLc1HQX0RX,_type:subNavigation,_updatedAt:2020-02-18T20:19:49Z,children:,is_active:true,name:Brain Cancer,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/brain},{_createdAt:2020-02-17T16:40:46Z,_id:9e97ba1a-e662-4069-b67a-94f2895260d4,_rev:5EFAHJWBnybshQjXN0qO1M,_type:subNavigation,_updatedAt:2020-02-18T20:20:58Z,children:,is_active:true,name:Breast Cancer,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/breast},{_createdAt:2020-02-17T16:45:38Z,_id:7a433f2a-1bb3-4b40-a9cd-657d30a350f2,_rev:yXmOfWU2bW5E5GKGf5sSNA,_type:subNavigation,_updatedAt:2020-02-18T20:21:13Z,children:,is_active:true,name:Gastrointestinal Cancer,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/gastrointestinal},{_createdAt:2020-02-17T16:44:48Z,_id:81a6556f-c6a2-4b75-9e86-15370ffddaec,_rev:5EFAHJWBnybshQjXN0qUoW,_type:subNavigation,_updatedAt:2020-02-18T20:21:19Z,children:,is_active:true,name:Genitourinary Cancers,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/genitourinary},{_createdAt:2020-04-21T14:45:25Z,_id:c639bdf3-1f2d-48c3-9a52-dfe7837c5a95,_rev:YME9LEWLx2jOfxHhPmeJeQ,_type:subNavigation,_updatedAt:2020-08-25T17:57:21Z,children:,is_active:true,name:Gynecologic Cancers,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/gynecologic},{_createdAt:2020-02-17T16:47:24Z,_id:727a9345-c1c8-41c6-99be-911dc1f83588,_rev:55uRbzIrtDDwUF1TIkziPZ,_type:subNavigation,_updatedAt:2020-02-18T20:21:33Z,children:,is_active:true,name:Head \u0026 Neck Cancers,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/head-and-neck},{_createdAt:2020-02-17T16:47:48Z,_id:67fbb0bc-6160-4b3d-8818-15e442722319,_rev:55uRbzIrtDDwUF1TIkzjaq,_type:subNavigation,_updatedAt:2020-02-18T20:21:39Z,children:,is_active:true,name:Hematology,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/hematology},{_createdAt:2020-02-17T16:08:20Z,_id:9e269564-4108-4b0d-a7f4-4aa9efbd99e3,_rev:xCSubv3YiXQgamBpuP9AVq,_type:subNavigation,_updatedAt:2020-04-18T00:43:55Z,children:,is_active:true,name:Leukemias,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/leukemias},{_createdAt:2020-02-17T16:49:10Z,_id:fd7078bb-b5a2-4fda-8a48-796dd6babacc,_rev:NgOVPrTlffdjZLc1HQXtpo,_type:subNavigation,_updatedAt:2020-02-18T20:21:55Z,children:,is_active:true,name:Lung Cancer,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/lung},{_createdAt:2020-02-17T16:49:51Z,_id:f19384ac-42cc-461e-93fe-70a50827fbea,_rev:Ns17kavMOOUMlsOJRlPB0r,_type:subNavigation,_updatedAt:2020-02-18T20:22:02Z,children:,is_active:true,name:Lymphomas,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/lymphoma},{_createdAt:2020-02-17T16:50:37Z,_id:e910db58-ac81-4f5f-87a5-5860bfe7f811,_rev:5EFAHJWBnybshQjXN0qteO,_type:subNavigation,_updatedAt:2020-02-18T20:22:08Z,children:,is_active:true,name:Melanoma,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/melanoma},{_createdAt:2020-02-17T16:53:19Z,_id:3a2676da-fcac-48bd-8d97-4b5e2d90fb79,_rev:NgOVPrTlffdjZLc1HQY0T6,_type:subNavigation,_updatedAt:2020-02-18T20:22:13Z,children:,is_active:true,name:Sarcoma,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/sarcoma},{_createdAt:2020-02-17T16:53:42Z,_id:0ad1eb44-b9c7-495a-8aaa-4f0920249812,_rev:5EFAHJWBnybshQjXN0r0RY,_type:subNavigation,_updatedAt:2020-02-18T20:22:19Z,children:,is_active:true,name:Skin Cancers,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/skin-cancers},{_createdAt:2020-02-17T16:54:08Z,_id:81ca3ade-90d4-4f9a-92f3-9a560c08e68f,_rev:P2fqWjUvpqx0razYmm50eB,_type:subNavigation,_updatedAt:2020-02-18T20:22:26Z,children:,is_active:true,name:Thyroid Cancers,navParent:{_ref:00c44d93-b1a5-4c54-a200-43c9fc5eda04,_type:reference},url:/clinical/thyroid},url:/clinical},{_createdAt:2023-02-03T16:22:37Z,_id:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_rev:vyEOe6El8eq2lqoxy0ZtVs,_type:subNavigation,_updatedAt:2023-02-03T16:22:57Z,is_active:true,name:Spotlight,navParent:null,subQuery:{_createdAt:2023-04-12T17:47:54Z,_id:6eed3158-24d0-433d-8b12-126a631fd9eb,_rev:VpFtOqnpB0gBKEOqbp5i3A,_type:subNavigation,_updatedAt:2025-06-09T19:09:45Z,children:,is_active:true,name:Myeloma,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:1,url:/clinical/multiple-myeloma-rc},{_createdAt:2023-04-12T17:48:42Z,_id:b862d091-d19b-4d19-be03-5d9dfef478cf,_rev:lAqAjO9enKu6RkbpMQ3Bxc,_type:subNavigation,_updatedAt:2025-06-09T19:11:10Z,children:,is_active:true,name:Chronic Lymphocytic Leukemia,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:2,url:/clinical/cll},{_createdAt:2023-04-12T17:49:18Z,_id:876c3443-0dfa-4297-be95-5e9c357ae3fa,_rev:lAqAjO9enKu6RkbpMQ3As6,_type:subNavigation,_updatedAt:2025-06-09T19:10:55Z,children:,is_active:true,name:Gynecologic Cancers,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:3,url:/clinical/gynecologic},{_createdAt:2023-04-12T17:49:52Z,_id:dec720c8-7836-4637-81eb-e91b468d1f0b,_rev:VpFtOqnpB0gBKEOqbp5sOi,_type:subNavigation,_updatedAt:2025-06-09T19:11:34Z,children:,is_active:true,name:Genomic Testing,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:4,url:/clinical/genomic-testing},{_createdAt:2023-04-12T17:50:21Z,_id:0aaaf942-8ec9-45fe-a618-1109dd532881,_rev:SRIDOFOqB0qAooPv9B4nur,_type:subNavigation,_updatedAt:2025-06-09T19:12:02Z,children:,is_active:true,name:Melanoma,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:5,url:/clinical/melanoma},{_createdAt:2023-04-12T17:51:03Z,_id:7dcc43f8-5af4-48ca-8b90-f799cfac13a9,_rev:SRIDOFOqB0qAooPv9B4oyu,_type:subNavigation,_updatedAt:2025-06-09T19:12:30Z,children:,is_active:true,name:Genitourinary Cancers,navParent:{_ref:6aceb802-f8d6-4f9c-bb7f-4c79880e30f3,_type:reference},sortOrder:6,url:/clinical/genitourinary},url:/spotlight},site_setting:{_createdAt:2020-02-21T05:36:56Z,_id:siteSettings,_rev:IZuOIwVTy0a65LAT2tklSX,_type:siteSettings,_updatedAt:2025-05-21T16:44:12Z,address:{addressCountry:United States of America,addressLocality:Cranbury,addressRegion:New Jersey,postalCode:08512,streetAddress:2 Commerce Drive},alternateName:TargetedOnc,contactPoint:{email:info@mjhlifesciences.com,telephone:609-716-7777},creativeLayout:null,creativeLayoutLatestNews:null,description:Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.,employees:Silas Inman,Kristie Kahl,Dylann Cohn-Emery,enableSanity2:true,footerLinks:{_key:e777ffb1d452,_type:urlArray,title:About Us,url:/about},{_key:787fe8da0e70,_type:urlArray,title:Advertise,url:/advertise},{_key:c72147473934,_type:urlArray,title:Contact Us,url:/contactus},{_key:59535aeda934,_type:urlArray,blank:true,title:CureToday.com,url:https://www.curetoday.com},{_key:b07011c84088,_type:urlArray,blank:true,title:CancerNetwork.com,url:https://www.cancernetwork.com},{_key:7ac6203e0daa,_type:urlArray,blank:true,title:OncLive.com,url:https://www.onclive.com},{_key:931a2ea79b4f,_type:urlArray,blank:true,title:OncNursingNews.com,url:https://www.oncnursingnews.com/},{_key:1360aae6fd9c,_type:urlArray,blank:true,title:Do Not Sell My Information,url:https://www.mjhlifesciences.com/ccpa?domainwww.targetedonc.com},{_key:4a0a5c702866,_type:urlArray,blank:true,title:Privacy,url:/privacy},{_key:bc5d49dca2a6,_type:urlArray,blank:true,title:Terms \u0026 Conditions,url:/terms},{_key:d27f1c832f6e,_type:urlArray,title:Editorial Board,url:/editorial-board},founder:MJH Life Sciences,foundingDate:2013-09-07,gaID:UA-155582410-4,UA-11140057-50,keywords:cancer,oncology,name:Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways,orangizationName:Targeted Healthcare Communications,siteURL:www.targetedonc.com,socialLinks:{_key:dd249d421ed8,_type:urlArray,blank:true,title:Facebook,url:https://www.facebook.com/TargetedOnc/},{_key:339fce0fd394,_type:urlArray,blank:true,title:Linkedin,url:https://www.linkedin.com/company/targetedonc},{_key:e0b7d008d270,_type:urlArray,blank:true,title:X,url:https://twitter.com/TargetedOnc},{_key:d584ff15079a,_type:urlArray,blank:true,title:YouTube,url:https://www.youtube.com/user/TargetedHC},{_key:b92ba97e0129,_type:urlArray,blank:true,title:Instagram,url:https://www.instagram.com/targetedoncology/}},clinicalData:{_id:topic_brain,children:,identifier:brain,name:BRAIN CANCER,sortOrder:null},{_id:topic_breast,children:{_id:2af445a4-7417-4d79-8503-f5688976670d,identifier:her2-positive,name:HER2 Breast Cancer,sortOrder:null},identifier:breast,name:BREAST CANCER,sortOrder:null},{_id:topic_genitourinary,children:{_id:topic_bladder,identifier:bladder,name:Bladder Cancer,sortOrder:null},{_id:topic_prostate,identifier:prostate,name:Prostate Cancer,sortOrder:null},{_id:topic_rcc,identifier:rcc,name:Renal Cell Carcinoma,sortOrder:null},identifier:genitourinary,name:GENITOURINARY CANCERS,sortOrder:null},{_id:topic_genomic-testing,children:{_id:topic_liquid-biopsies,identifier:liquid-biopsies,name:Liquid Biopsies,sortOrder:null},identifier:genomic-testing,name:GENOMIC TESTING,sortOrder:null},{_id:topic_gastrointestinal,children:{_id:topic_colorectal,identifier:colorectal,name:Colorectal Cancer,sortOrder:null},{_id:topic_gist,identifier:gist,name:GIST,sortOrder:null},{_id:topic_gastric,identifier:gastric,name:Gastric Cancer,sortOrder:null},{_id:topic_hcc,identifier:hcc,name:HCC,sortOrder:null},identifier:gastrointestinal,name:GI CANCERS,sortOrder:null},{_id:topic_gynecologic,children:{_id:0f41e796-6d7f-4584-b1a3-7a5b6dcaafeb,identifier:cervical-cancer,name:Cervical Cancer,sortOrder:1},{_id:8ab4e79d-0825-4e5f-853e-275f19687abb,identifier:endometrial-cancer,name:Endometrial Cancer,sortOrder:2},{_id:topic_ovarian,identifier:ovarian,name:Ovarian Cancer,sortOrder:null},identifier:gynecologic,name:GYNECOLOGIC CANCERS,sortOrder:3},{_id:topic_head-and-neck,children:,identifier:head-and-neck,name:HEAD \u0026 NECK CANCERS,sortOrder:null},{_id:topic_hematology,children:{_id:c075a853-1b90-4e27-86fc-38c0e19d2b43,identifier:bone-marrow-and-sct,name:Bone Marrow \u0026 Stem Cell Transplant,sortOrder:2},identifier:hematology,name:HEMATOLOGY,sortOrder:4},{_id:topic_immunotherapy,children:{_id:topic_car-t-cell-therapy,identifier:car-t-cell-therapy,name:CAR T-Cell Therapy,sortOrder:null},identifier:immunotherapy,name:IMMUNOTHERAPY,sortOrder:null},{_id:topic_leukemias,children:{_id:topic_aml,identifier:aml,name:AML,sortOrder:null},{_id:topic_cll,identifier:cll,name:Chronic Lymphocytic Leukemia,sortOrder:null},{_id:topic_cml,identifier:cml,name:Chronic Myeloid Leukemia,sortOrder:null},identifier:leukemias,name:LEUKEMIAS,sortOrder:null},{_id:topic_lung,children:{_id:topic_biomarker-lung-cancer,identifier:biomarker-lung-cancer,name:Biomarker-Driven Lung Cancer,sortOrder:1},{_id:topic_egfr-positive-lungcancer,identifier:egfr-positive-lungcancer,name:EGFR+ Lung Cancer,sortOrder:null},{_id:28678b45-9ec5-44f3-a021-b15de3e14f99,identifier:met-targeted-therapy,name:MET-Targeted Therapy,sortOrder:null},{_id:35a23144-2f16-464f-aa37-3d0e67670251,identifier:small-cell-lung-cancer,name:Small Cell Lung Cancer,sortOrder:6},identifier:lung,name:LUNG CANCER,sortOrder:5},{_id:topic_lymphoma,children:{_id:topic_dlbcl,identifier:dlbcl,name:DLBCL,sortOrder:null},{_id:topic_follicularlymphoma,identifier:follicularlymphoma,name:Follicular Lymphoma,sortOrder:null},{_id:topic_mcl,identifier:mcl,name:Mantle Cell Lymphoma,sortOrder:null},identifier:lymphoma,name:LYMPHOMAS,sortOrder:null},{_id:topic_mpn,children:,identifier:mpn,name:MPNs,sortOrder:null},{_id:topic_multiple-myeloma-rc,children:,identifier:multiple-myeloma-rc,name:MULTIPLE MYELOMA,sortOrder:null},{_id:2eec1631-e17e-4608-9d51-65b1528314b9,children:,identifier:ntrk,name:NTRK GENE FUSIONS,sortOrder:null},{_id:topic_sarcoma,children:,identifier:sarcoma,name:SARCOMA,sortOrder:null},{_id:topic_skin-cancers,children:{_id:topic_melanoma,identifier:melanoma,name:Melanoma,sortOrder:null},identifier:skin-cancers,name:SKIN CANCERS,sortOrder:null},{_id:topic_thyroid,children:,identifier:thyroid,name:THYROID CANCERS,sortOrder:7},seo_data:,adLayer:{adSlotSelection:mobileLeaderBoard,docGroup:null,issue:null,multipleAdSlotSelection:null,targetType:Taxonomy,taxonomy:{_id:topic_thyroid,url:thyroid},url:null},isLiveSite:true,host:www.targetedonc.com,settings:{title:Targeted Oncology,networkID:4688,adUnit:targetedonc.com,liveDomain:www.targetedonc.com,publicationName:Targeted Oncology,logo:/TargetedOnc_logo.png,mobile_logo:/log_inverted.png,white_logo:/log_inverted.png,logoWidth:150px,logoHeight:56.5px,mobileLogoWidth:150px,mobileLogoHeight:56.5px,logoBannerHeight:80,logoPadding:2,enableEdgeCache:true,sMaxAge:300,subscribe:{href:/newsletter,text:Stay up to date on practice-changing data in community practice.},staleWhileRevalidate:359,megaMenuTaxName:clinical,sharingImageUrl:https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/TargetedOnc_1200x637.png,twitterHandle:@TargetedOnc,navigationOptions:{variant:2},gateEnabled:modal,scoutEnabled:true,scoutIconUrl:/TO_SCOUT-head-name 1.png,scoutUrl:https://scout-v2.targetedonc.com,scoutBeta:true}},targeting:{content_placement:home,document_url:home,document_group:,rootDocumentGroup:},data:{topArticles:{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-08-03T15:00:00.000Z,summary:A groundbreaking study reveals that Guardant Reveals liquid biopsy detects immunotherapy responses earlier, enhancing treatment decisions for advanced cancer patients.,thumbnail:{_type:mainImage,asset:{_ref:image-bf401f08b58804d8aa322d18ed8162f17a886f20-480x270-webp,_type:reference}},title:Blood-Based Monitoring Assay Predicts Immunotherapy Response in Advanced Cancers,url:blood-based-monitoring-assay-predicts-immunotherapy-response-in-advanced-cancers},{authors:{displayName:Targeted Oncology Staff,url:targeted-oncology-staff},published:2025-08-03T11:00:00.000Z,summary:In this weeks Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key discussions on trial access gaps.,thumbnail:{_type:mainImage,asset:{_ref:image-d15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500-png,_type:reference}},title:The Targeted Pulse: FDA Designations, Access Gaps, and Strategic Advances in Oncology,url:targeted-pulse-august-3},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-08-02T15:00:00.000Z,summary:A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapys side effects and improve patient outcomes.,thumbnail:{_type:mainImage,asset:{_ref:image-9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630-png,_type:reference}},title: Breast Cancer Trial Investigates Personalized Neoadjuvant Therapy,url:breast-cancer-trial-investigates-personalized-neoadjuvant-therapy},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-08-02T11:00:00.000Z,summary:The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining treatment standards.,thumbnail:{_type:mainImage,asset:{_ref:image-043eaa7256c7938046b287a4b9c883327737332a-480x269-png,_type:reference}},title:STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC,url:stride-regimen-shows-sustained-5-year-os-benefit-in-unresectable-hcc},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-08-01T19:00:00.000Z,summary:null,thumbnail:{_type:mainImage,asset:{_ref:image-d8002572ce924ce8b20bd3d30c37fd59c98909fb-1200x630-png,_type:reference}},title:Sustained Benefit in Advanced RCC with Pembrolizumab and Axitinib,url:sustained-benefit-in-advanced-rcc-with-pembrolizumab-and-axitinib},newsArticles:{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-08-01T15:00:00.000Z,summary:A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.,thumbnail:{_type:mainImage,asset:{_ref:image-2b0b1af7892f6fe1c5f062dbca1d5bff6cd42277-1200x630-png,_type:reference}},title:Rethinking Rectal Cancer End Points: pCR Not a Survival Surrogate,url:rethinking-rectal-cancer-end-points-pcr-not-a-survival-surrogate},{authors:{displayName:Benjamin Garmezy, MD,url:benjamin-garmezy-md},{displayName:Ralph J. Miller Jr, MD,url:ralph-j-miller-jr-md},published:2025-08-01T14:30:01.244Z,summary:In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.,thumbnail:{_type:mainImage,asset:{_ref:image-ff63693064a0f672c9d7296d1e04a22bbfe9bcea-6250x6250-png,_type:reference}},title:Advancing Prostate Cancer Treatment With Shared Decision-Making,url:advancing-prostate-cancer-treatment-with-shared-decision-making},{authors:{displayName:Targeted Oncology Staff,url:targeted-oncology-staff},published:2025-08-01T14:00:00.000Z,summary:July marks a transformative month in oncology with the FDAs groundbreaking approvals and updates, enhancing treatment options for various cancers.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:Julys Oncology Approvals: A Landmark Month for Cancer Treatment Advancements,url:july-2025-fda-news},{authors:{displayName:Tony Berberabe, MPH,url:tony-berberabe-mph},published:2025-08-01T13:00:00.000Z,summary:Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.,thumbnail:{_type:mainImage,asset:{_ref:image-97e6f8484a8dcb683b6c63f34cfef25e3f226129-1200x630-png,_type:reference}},title:Cabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases,url:cabozantinib-atezolizumab-improves-pfs-in-patients-with-mcrpc-and-extrapelvic-metastases},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-31T17:00:00.000Z,summary:Sanofis SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach.,thumbnail:{_type:mainImage,asset:{_ref:image-51b60866e10ef98361ed33e1665c3599f4c3c176-1200x630-png,_type:reference}},title:Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma,url:novel-gprc5d-mab-receives-fda-orphan-drug-designation-in-r-r-myeloma},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-31T15:00:00.000Z,summary:null,thumbnail:{_type:mainImage,asset:{_ref:image-acece1504d0b9509ea93d0f8913fdd54c47b2b13-1200x630-png,_type:reference}},title:Novel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet,url:novel-combinations-show-promise-in-resectable-nsclc-led-by-adc-chemo-immuno-triplet},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-31T14:00:00.000Z,summary:New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients.,thumbnail:{_type:mainImage,asset:{_ref:image-72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080-png,_type:reference}},title:Gedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer,url:gedatolisib-shows-impressive-pfs-in-hr-her2-breast-cancer},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-31T13:00:00.000Z,summary:Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization and combination therapy strategies.,thumbnail:{_type:mainImage,asset:{_ref:image-9381ea087c93c1b409ce03c7edc3221cf88aaf72-1200x630-png,_type:reference}},title:Advancing Metastatic Breast Cancer Treatment: Z-Endoxifen Nears IND Submission,url:advancing-metastatic-breast-cancer-treatment-z-endoxifen-nears-ind-submission},{authors:{displayName:Targeted Oncology Staff,url:targeted-oncology-staff},published:2025-07-30T21:30:11.245Z,summary:During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy. ,thumbnail:{_type:mainImage,asset:{_ref:image-5e919ccd6fc478982afe21a32e1a531eda659ebf-4528x2491-jpg,_type:reference}},title:Elimination of REMS Program Could Reduce Barriers to CAR T in DLBCL,url:elimination-of-rems-program-could-reduce-barriers-to-car-t-in-dlbcl},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-30T17:00:00.000Z,summary:FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and review process.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:CLD-201 Receives FDA Fast Track Designation Targeting Sarcoma,url:cld-201-receives-fda-fast-track-designation-targeting-sarcoma},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-30T15:00:00.000Z,summary:Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.,thumbnail:{_type:mainImage,asset:{_ref:image-0650ae1e17c7f6b3626d83e2e458ddeda9000adb-1200x630-png,_type:reference}},title:Optimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3,url:optimizing-cll-sll-therapy-pirtobrutinib-matches-ibrutinib-in-phase-3},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-30T14:00:00.000Z,summary:Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic pancreatic cancer patients.,thumbnail:{_type:mainImage,asset:{_ref:image-5af6e25b17d074d8c9c8cb627adfc1e12de90596-480x270-png,_type:reference}},title:Rintatolimod Plus Durvalumab Shows Encouraging Early Outcomes in Metastatic Pancreatic Cancer,url:rintatolimod-plus-durvalumab-shows-encouraging-early-outcomes-in-metastatic-pancreatic-cancer},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-30T13:00:00.000Z,summary:New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, improving patient outcomes significantly.,thumbnail:{_type:mainImage,asset:{_ref:image-f2bc6701ba527babea57a039e5867355c71b1181-480x270-webp,_type:reference}},title:Long-Term Follow-Up Affirms Ivosidenibs Sustained Benefit in IDH1-Mutated AML,url:long-term-follow-up-affirms-ivosidenib-s-sustained-benefit-in-idh1-mutated-aml},{authors:{displayName:Nino Balanchivadze, MD, FACP,url:nino-balanchivadze-md-facp},published:2025-07-29T21:00:18.592Z,summary:Nina Balanchivadze, MD, FACP, discusses how inclusive research begins at the community level by addressing barriers to trial participation.,thumbnail:{_type:mainImage,asset:{_ref:image-3c077dc6e8d995bace7e23044fc025f9fcb11af9-311x175-webp,_type:reference}},title:Breaking Trial Barriers Through Community-Inclusive Research,url:breaking-trial-barriers-through-community-inclusive-research},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-29T20:00:00.000Z,summary:AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in CLL care.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:FDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL,url:fda-review-underway-for-oral-venetoclax-acalabrutinib-combo-in-untreated-cll},{authors:{displayName:Jason M. Broderick,url:jason-m-broderick},published:2025-07-29T18:18:58.956Z,summary:The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:FDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors,url:fda-greenlights-trials-of-novel-adc-and-radiopharmaceutical-in-solid-tumors},{authors:{displayName:Tony Berberabe, MPH,url:tony-berberabe-mph},published:2025-07-29T15:00:00.000Z,summary:The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed or refractory patients with AML or MDS.,thumbnail:{_type:mainImage,asset:{_ref:image-24dcd465d25a34500da55b7948918f713916e486-1920x1080-png,_type:reference}},title:BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS,url:btx-a51-demonstrates-tolerability-and-manageable-safety-profile-in-patients-with-r-r-aml-mds},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-29T14:00:00.000Z,summary:MAIA Biotechnologys ateganosine gains FDA fast track status, offering hope for advanced NSCLC patients with limited treatment options.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:Ateganosine Receives FDA Fast Track Designation for NSCLC,url:ateganosine-receives-fda-fast-track-designation-for-nsclc},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-29T13:00:00.000Z,summary:Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.,thumbnail:{_type:mainImage,asset:{_ref:image-72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080-png,_type:reference}},title:Long-Term Outcomes Bolstered by Atezolizumab in Early-Stage Triple-Negative Breast Cancer,url:long-term-outcomes-bolstered-by-atezolizumab-in-early-stage-triple-negative-breast-cancer},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-28T21:00:00.000Z,summary:null,thumbnail:{_type:mainImage,asset:{_ref:image-6e72fc30e74f70c717a633fe2ba63145c1831668-640x360-png,_type:reference}},title:Home-Based Mitomycin Instillation Shows Promise for Low-Grade Bladder Cancer,url:home-based-mitomycin-instillation-shows-promise-for-low-grade-bladder-cancer},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-28T14:00:00.000Z,summary:A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment.,thumbnail:{_type:mainImage,asset:{_ref:image-a421ea3b3863d973a242702a8cf41c330362014f-480x270-png,_type:reference}},title:Metformin Fails to Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer,url:metformin-fails-to-improve-survival-in-metastatic-hormone-sensitive-prostate-cancer},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-28T13:00:00.000Z,summary:Durvalumabs breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer,url:durvalumab-earns-fda-priority-review-for-early-stage-gastric-cancer},{authors:{displayName:Targeted Oncology Staff,url:targeted-oncology-staff},published:2025-07-27T11:00:00.000Z,summary:This week: FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and TNBC research aims for safer treatments.,thumbnail:{_type:mainImage,asset:{_ref:image-d15bcd0018fe0def5423fc6997c23fe4e938c2b7-500x500-png,_type:reference}},title:The Targeted Pulse: Key Oncology Updates and Breakthroughs,url:the-targeted-pulse-july-27},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-26T15:00:00.000Z,summary:A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.,thumbnail:{_type:mainImage,asset:{_ref:image-72def5e8854903a11bede091e0b6b4278f3206b9-1920x1080-png,_type:reference}},title:Triplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status,url:triplet-therapy-shows-promise-for-advanced-tnbc-regardless-of-pd-l1-status},{authors:{displayName:Sabrina Serani,url:sabrina-serani},published:2025-07-25T17:04:00.000Z,summary:FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.,thumbnail:{_type:mainImage,asset:{_ref:image-a255cd9f64cadd75779a0db0cb12beaf286401ea-1200x1200-png,_type:reference}},title:FDA Grants Priority Review to Tab-Cel for EBV+ PTLD After Prior Therapies,url:fda-grants-priority-review-to-tab-cel-for-ebv-ptld-after-prior-therapies},latestVideos:{thumbnail:{asset:{_createdAt:2025-08-01T18:36:33Z,_id:image-11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630-png,_rev:1EWWyiYM4mZ4FdrmsKg8ge,_type:sanity.imageAsset,_updatedAt:2025-08-01T18:36:33Z,assetId:11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MBEooh0X1S~9ia?GivxVxtV9c?axWn#Nf,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#4f3026,foreground:#fff,population:2.4,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043062,foreground:#fff,population:0.76,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#a3856a,foreground:#fff,population:8.91,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#cfbea6,foreground:#000,population:1.21,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#6390bd,foreground:#fff,population:1.56,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#a3856a,foreground:#fff,population:8.91,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#2b5c93,foreground:#fff,population:4.79,title:#fff}}},mimeType:image/png,originalFilename:McGregor TN.png,path:images/0vv8moc6/targetedonc/11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png,sha1hash:11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5,size:1091452,uploadId:JM0YKnmMpSBcDIy7BUAx6Rj0LBPnAOuL,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/11a5fa68df55dd44ac416d87e0d4cbf1bf9495b5-1200x630.png}},title:Frontline Metastatic RCC Therapy Improved With Long-Term Data,url:frontline-metastatic-rcc-therapy-improved-with-long-term-data,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-17T14:54:50Z,_id:image-d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080-png,_rev:Jk7iJL0vFuPNkOJR7aK9VY,_type:sanity.imageAsset,_updatedAt:2025-07-17T14:54:50Z,assetId:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MTJ6d8^~W_3oy00yEE2NGjYD*-UMxD$Rk,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:false,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#28405d,foreground:#fff,population:0.65,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#a4aabd,foreground:#000,population:1.89,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#eec88a,foreground:#000,population:0.39,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#567ca5,foreground:#fff,population:0.19,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#f0a131,foreground:#000,population:3.82,title:#fff}}},mimeType:image/png,originalFilename:OluwoleHS.png,path:images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png,sha1hash:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,size:885498,uploadId:KT2O2X3dXRzUME1GIeBTDSqdg8QvpsZ4,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png}},title:TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-Cell Therapy for Second-Line R/R LBCL,url:transform-trial-clinical-perspectives-in-liso-cel-car-t-cell-therapy-for-second-line-r-r-lbcl,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-06-11T13:21:51Z,_id:image-9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080-png,_rev:qk1Ao5T1LSVRaesiu6taGL,_type:sanity.imageAsset,_updatedAt:2025-06-11T13:21:51Z,assetId:9674ba40029ed300b868fe0d1554b93d1c883dc6,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MJKx9$-;Mxt8~q00%LM{a$M{EAMxtRIT9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#161423,foreground:#fff,population:4.99,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:15.25,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:15.25,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#c6b49d,foreground:#000,population:0.34,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#c87c64,foreground:#fff,population:0.01,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#577798,foreground:#fff,population:0.24,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#c4745c,foreground:#fff,population:0,title:#fff}}},mimeType:image/png,originalFilename:marketing image (5).png,path:images/0vv8moc6/targetedonc/9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png,sha1hash:9674ba40029ed300b868fe0d1554b93d1c883dc6,size:1004214,uploadId:ktNYod5jfSwm6Dj6L1CkK8TeMAefGOHN,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/9674ba40029ed300b868fe0d1554b93d1c883dc6-1920x1080.png}},title:The Evolving MPN Landscape: Future Therapeutic Directions and Addressing Unmet Needs in Myelofibrosis and Polycythemia Vera,url:the-evolving-mpn-landscape-future-therapeutic-directions-and-addressing-unmet-needs-in-myelofibrosis-and-polycythemia-vera,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T14:14:29Z,_id:image-f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f482a6eeaf6072e37003294e2517c732a4142ca0,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:M7Dcd*03JD^LJ6}jDi-xoD$Ae$x-OOrIr,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAA7DAAAOwwHHb6hkAAAC+ElEQVR4nBXDa09aBwCA4fNHtkyrJm2ZVlEs3sBLuahQBadYREEpp1o8gtyFU8AL4KGIWKirnYwOu6xpbU2atsm6D90l+7RP+0Pvsid5hBs3bfT1ORkY9KAZWKNft4F2IkCXfpsW7f+D9I4HMFhDTNqjmG1RZh0p3KKCFH7KtvwjG6k6U6tF2gwyQrd6Ef2oF6N5kwlLBO1Ugu6JCDcGJa5r/ejMQTzeJH5Jxul6yNTUIvO2FR7Fd3l9ccmXz3/w4eojiVSJLnMUYUgvYv8uyrI7i8unYFg8QDUWobV3Hc3YJg/WZXL7hyRiOzjsDuZMFrx350j6RF6dPePfv//iny+/kd9TUBskhBFDgIWlNB5fAfdGmblVhdumGO29PnSTEslkjuPSEcn4Dg9XvGREiccbQbJuD0eJOJ+v3vH7pw9kUvuo9SLCt9oHDJojjNrT6Ob3GbFl6NYHaFPfRz8dICUXOCmXyWf3yIXjVMMyNSlObmWNQ2mTd80mH9++ZSeaRj3kQWjtF+m4E6HDkqbNukv7VJpWXYiW/nX0lhDJVJ4n5TInBYXTzAHPIhmO7wfJOz0cSRKvzuu8/vkXQsEk3dolhJaJMNdmsnwzu89XM3m+th/SYt3l2miI0dkIO3KeSqnEk2KJs1yRp6E0ewteEncXKEhbXPxQp9m4QPLHudXnQGi3yKjuKXQuH6NyVej01LjlrqCyyIzNxYglDygpRUqPK1SKVYqhDGGrC9EwQ3orTOP8J140XrIl7dDTN4/Q6cgz7Kti2q4zHXmBNdZkMnTO7YU9xmbDhBMFlMoZ+e/fkD+9Ipso4p9dZtloIxZM8bzxhkbzkuD2LhqtE6HbpTAsVrkjPcccOGc6VMfor6GejjJg2sIbqxGpvid49idS5VdEScFpdWMzOVkTH5EuviSrXHBvWaar14Vw3SrTtXRIj/sYtaeCxnuCej5Lh2YV1dA642INU+ISY/yScfEUnSXMiM7N4IibYaMfkz2JYSZBz4CP1psO/gMid+xV9JVwUwAAAABJRU5ErkJggg,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c58,foreground:#fff,population:0.6,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042a5d,foreground:#fff,population:0.55,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#c2d0ef,foreground:#000,population:0.67,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#ac6474,foreground:#fff,population:0.01,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#4476a1,foreground:#fff,population:3.51,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:Rclbp2MfpDrGjAmM4uiiu,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:Sands thumb.png,path:images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png,sha1hash:f482a6eeaf6072e37003294e2517c732a4142ca0,size:1011432,uploadId:0RTcHyHZqXniHu0l96NoILDAznMaDNnK,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png}},title:The Future of Dato-DXd in Lung Cancer and Beyond,url:the-future-of-dato-dxd-in-lung-cancer-and-beyond,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-06-30T19:58:31Z,_id:image-a80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080-png,_rev:KmnbQZZm9OkV3zxRYcAW17,_type:sanity.imageAsset,_updatedAt:2025-06-30T19:58:31Z,assetId:a80319a0a358bf8606ff284b0e95e1607bdb29dc,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MVKBXZoz?ws+%300$#D*f,Ip59NeROjFoH,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:false,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#3a4b5d,foreground:#fff,population:0.98,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.89,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.89,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#d5bcae,foreground:#000,population:1.43,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#e6cec2,foreground:#000,population:0.2,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#6c94ab,foreground:#fff,population:3.87,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#45b8ef,foreground:#000,population:2.22,title:#fff}}},mimeType:image/png,originalFilename:TarantinoHS.png,path:images/0vv8moc6/targetedonc/a80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png,sha1hash:a80319a0a358bf8606ff284b0e95e1607bdb29dc,size:818803,uploadId:vnpgG15tF4KfP9uIbWs3gaVLMMYkmLtW,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/a80319a0a358bf8606ff284b0e95e1607bdb29dc-1920x1080.png}},title:Implementation Strategies: Real-World Treatment Implementation,url:implementation-strategies-real-world-treatment-implementation,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-03-05T15:10:42Z,_id:image-130ebc4b052e83d065b139a5a2902d8615086671-1920x1080-png,_rev:O4vU95h3tPdx254F3HugXR,_type:sanity.imageAsset,_updatedAt:2025-03-05T15:10:42Z,assetId:130ebc4b052e83d065b139a5a2902d8615086671,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MCJ*xIR|OsEK?^00^lD*xvIU17xVsITIA,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#315d6f,foreground:#fff,population:0.15,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:15.48,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:15.48,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#cec0ac,foreground:#000,population:3.04,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#e99fa4,foreground:#000,population:0.05,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#8b7c72,foreground:#fff,population:13.04,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#406c9d,foreground:#fff,population:0.03,title:#fff}}},mimeType:image/png,originalFilename:marketing image (5).png,path:images/0vv8moc6/targetedonc/130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png,sha1hash:130ebc4b052e83d065b139a5a2902d8615086671,size:885140,uploadId:19fjrB1O2pEhenlcZJujaQZ1htHgw4Kp,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/130ebc4b052e83d065b139a5a2902d8615086671-1920x1080.png}},title:The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape ,url:the-evolving-role-of-lenvatinib-in-the-hcc-therapeutic-landscape,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T14:14:29Z,_id:image-f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f482a6eeaf6072e37003294e2517c732a4142ca0,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:M7Dcd*03JD^LJ6}jDi-xoD$Ae$x-OOrIr,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c58,foreground:#fff,population:0.6,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042a5d,foreground:#fff,population:0.55,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#c2d0ef,foreground:#000,population:0.67,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#ac6474,foreground:#fff,population:0.01,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#4476a1,foreground:#fff,population:3.51,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:Rclbp2MfpDrGjAmM4uiiu,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:Sands thumb.png,path:images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png,sha1hash:f482a6eeaf6072e37003294e2517c732a4142ca0,size:1011432,uploadId:0RTcHyHZqXniHu0l96NoILDAznMaDNnK,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png}},title:The Future of Dato-DXd in Lung Cancer and Beyond,url:the-future-of-dato-dxd-in-lung-cancer-and-beyond,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T14:14:29Z,_id:image-f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f482a6eeaf6072e37003294e2517c732a4142ca0,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:M7Dcd*03JD^LJ6}jDi-xoD$Ae$x-OOrIr,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c58,foreground:#fff,population:0.6,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042a5d,foreground:#fff,population:0.55,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#c2d0ef,foreground:#000,population:0.67,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#ac6474,foreground:#fff,population:0.01,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#4476a1,foreground:#fff,population:3.51,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:Rclbp2MfpDrGjAmM4uiiu,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:Sands thumb.png,path:images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png,sha1hash:f482a6eeaf6072e37003294e2517c732a4142ca0,size:1011432,uploadId:0RTcHyHZqXniHu0l96NoILDAznMaDNnK,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png}},title:Toxicity Management for Dato-DXd: Stomatitis, Eye Issues, and ILD,url:toxicity-management-for-dato-dxd-stomatitis-eye-issues-and-ild,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-06-26T16:22:02Z,_id:image-4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080-png,_rev:K1P8lao0rET3lCXgIP4reW,_type:sanity.imageAsset,_updatedAt:2025-06-26T16:22:02Z,assetId:4de9ac5373899e15bd0c1b49fdc8531728deed5a,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MLJko-;_Nsn.800xuIUM{M{x_RjIUM{IU,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#364661,foreground:#fff,population:0.88,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:14.18,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:14.18,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#ceb29c,foreground:#000,population:0.27,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#d3928d,foreground:#000,population:0.91,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#8f6366,foreground:#fff,population:0.14,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#3c6697,foreground:#fff,population:0.09,title:#fff}}},mimeType:image/png,originalFilename:Marketing Image (27).png,path:images/0vv8moc6/targetedonc/4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png,sha1hash:4de9ac5373899e15bd0c1b49fdc8531728deed5a,size:1026013,uploadId:i0SafuwoAE4MOY6GMgC7mCPVaWHHBuxn,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/4de9ac5373899e15bd0c1b49fdc8531728deed5a-1920x1080.png}},title:Future Horizons in SCAC: Current Standards and Next-Generation Treatment Strategies,url:future-horizons-in-scac-current-standards-and-next-generation-treatment-strategies,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T14:14:29Z,_id:image-f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f482a6eeaf6072e37003294e2517c732a4142ca0,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:M7Dcd*03JD^LJ6}jDi-xoD$Ae$x-OOrIr,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c58,foreground:#fff,population:0.6,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042a5d,foreground:#fff,population:0.55,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#94aecb,foreground:#000,population:5.81,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#c2d0ef,foreground:#000,population:0.67,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#ac6474,foreground:#fff,population:0.01,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#4476a1,foreground:#fff,population:3.51,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:Rclbp2MfpDrGjAmM4uiiu,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:Sands thumb.png,path:images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png,sha1hash:f482a6eeaf6072e37003294e2517c732a4142ca0,size:1011432,uploadId:0RTcHyHZqXniHu0l96NoILDAznMaDNnK,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f482a6eeaf6072e37003294e2517c732a4142ca0-1200x630.png}},title:Behind the FDA Approval of Dato-DXd in Lung Cancer With Dr Sands,url:behind-the-fda-approval-of-dato-dxd-in-lung-cancer-with-dr-sands,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-17T14:54:50Z,_id:image-d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080-png,_rev:Jk7iJL0vFuPNkOJR7aK9VY,_type:sanity.imageAsset,_updatedAt:2025-07-17T14:54:50Z,assetId:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MTJ6d8^~W_3oy00yEE2NGjYD*-UMxD$Rk,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:false,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#28405d,foreground:#fff,population:0.65,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#a4aabd,foreground:#000,population:1.89,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#eec88a,foreground:#000,population:0.39,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#567ca5,foreground:#fff,population:0.19,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#f0a131,foreground:#000,population:3.82,title:#fff}}},mimeType:image/png,originalFilename:OluwoleHS.png,path:images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png,sha1hash:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,size:885498,uploadId:KT2O2X3dXRzUME1GIeBTDSqdg8QvpsZ4,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png}},title:TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-Cell Therapy for Second-Line R/R LBCL,url:transform-trial-clinical-perspectives-in-liso-cel-car-t-cell-therapy-for-second-line-r-r-lbcl,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-17T14:54:50Z,_id:image-d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080-png,_rev:Jk7iJL0vFuPNkOJR7aK9VY,_type:sanity.imageAsset,_updatedAt:2025-07-17T14:54:50Z,assetId:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MTJ6d8^~W_3oy00yEE2NGjYD*-UMxD$Rk,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7777777777777777,height:1080,width:1920},hasAlpha:true,isOpaque:false,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#28405d,foreground:#fff,population:0.65,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#043c74,foreground:#fff,population:13.99,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#a4aabd,foreground:#000,population:1.89,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#eec88a,foreground:#000,population:0.39,title:#000},muted:{_type:sanity.imagePaletteSwatch,background:#567ca5,foreground:#fff,population:0.19,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#f0a131,foreground:#000,population:3.82,title:#fff}}},mimeType:image/png,originalFilename:OluwoleHS.png,path:images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png,sha1hash:d8191f8314b2e0bdae9be72ff47d591b9e7f98d1,size:885498,uploadId:KT2O2X3dXRzUME1GIeBTDSqdg8QvpsZ4,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/d8191f8314b2e0bdae9be72ff47d591b9e7f98d1-1920x1080.png}},title:CAR T in Practice: Translating ZUMA-7 Trial Data for Axi-Cel in Second-Line Treatment Decisions,url:car-t-in-practice-translating-zuma-7-trial-data-for-axi-cel-in-second-line-treatment-decisions,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T15:15:51Z,_id:image-f745d66774d828898d4c380047f710dd34962fe2-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f745d66774d828898d4c380047f710dd34962fe2,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MHFO_,5a01:~_NxEZ}bJxWNGER$$%1g3Rj,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c59,foreground:#fff,population:0.64,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042b5e,foreground:#fff,population:0.53,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#926d56,foreground:#fff,population:8.79,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#cdb2a0,foreground:#000,population:0.89,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#ecb48c,foreground:#000,population:0,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#926d56,foreground:#fff,population:8.79,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#47739d,foreground:#fff,population:3.75,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:GiMpqKJCnk78-Pz7D8ydn,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:McDaniel thumb.png,path:images/0vv8moc6/targetedonc/f745d66774d828898d4c380047f710dd34962fe2-1200x630.png,sha1hash:f745d66774d828898d4c380047f710dd34962fe2,size:1057296,uploadId:oJpcgRHJyBlVidqUBeWF9VJUq3BmlaSm,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f745d66774d828898d4c380047f710dd34962fe2-1200x630.png}},title:Fertility Preservation in Patients With Cancer: Key Takeaways for Oncologists,url:fertility-preservation-in-patients-with-cancer-key-takeaways-for-oncologists,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-28T15:15:51Z,_id:image-f745d66774d828898d4c380047f710dd34962fe2-1200x630-png,_rev:SwbV0G9qs3L20KsC4YkS24,_type:sanity.imageAsset,_updatedAt:2025-07-29T20:12:26Z,assetId:f745d66774d828898d4c380047f710dd34962fe2,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MHFO_,5a01:~_NxEZ}bJxWNGER$$%1g3Rj,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.9047619047619047,height:630,width:1200},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#2c2c59,foreground:#fff,population:0.64,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#042b5e,foreground:#fff,population:0.53,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#926d56,foreground:#fff,population:8.79,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#cdb2a0,foreground:#000,population:0.89,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#ecb48c,foreground:#000,population:0,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#926d56,foreground:#fff,population:8.79,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#47739d,foreground:#fff,population:3.75,title:#fff}}},mimeType:image/png,opt:{media:{tags:{_key:GiMpqKJCnk78-Pz7D8ydn,_ref:cTuYRRr5hMhGNsRkTM1RDH,_type:reference,_weak:true}}},originalFilename:McDaniel thumb.png,path:images/0vv8moc6/targetedonc/f745d66774d828898d4c380047f710dd34962fe2-1200x630.png,sha1hash:f745d66774d828898d4c380047f710dd34962fe2,size:1057296,uploadId:oJpcgRHJyBlVidqUBeWF9VJUq3BmlaSm,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/f745d66774d828898d4c380047f710dd34962fe2-1200x630.png}},title:Challenges of Access to Fertility Preservation in the US,url:challenges-of-access-to-fertility-preservation-in-the-us,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Breaking Barriers: Future Directions in CLL/SLL Treatment,url:breaking-barriers-future-directions-in-cll-sll-treatment,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Real-World Use of Frontline BTK Inhibitor Therapies,url:real-world-use-of-frontline-btk-inhibitor-therapies,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Expert Insights: Emerging Combination Strategies in Treatment-Naive CLL,url:expert-insights-emerging-combination-strategies-in-treatment-naive-cll,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Comprehensive Approaches for Managing Therapeutic Safety in TN CLL,url:comprehensive-approaches-for-managing-therapeutic-safety-in-tn-cll,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:MRD-Guided Therapy: Current and Future Practices,url:mrd-guided-therapy-current-and-future-practices,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Evidence-Based Strategies for Frontline Therapies in TN CLL,url:evidence-based-strategies-for-frontline-therapies-in-tn-cll,link:/view/undefined},{thumbnail:{asset:{_createdAt:2025-07-29T15:08:33Z,_id:image-c3816195de60a1c9a3186cb359096b06bf6cedac-944x532-png,_rev:sVhWHsjJdy0g7HLPAdmNDL,_type:sanity.imageAsset,_updatedAt:2025-07-29T15:08:33Z,assetId:c3816195de60a1c9a3186cb359096b06bf6cedac,extension:png,metadata:{_type:sanity.imageMetadata,blurHash:MSH_P%MR+oe_NyFxuM{oMNG00RQn*R*9F,dimensions:{_type:sanity.imageDimensions,aspectRatio:1.7744360902255638,height:532,width:944},hasAlpha:true,isOpaque:true,lqip:data:image/png;base64,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,palette:{_type:sanity.imagePalette,darkMuted:{_type:sanity.imagePaletteSwatch,background:#59382e,foreground:#fff,population:0.95,title:#fff},darkVibrant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},dominant:{_type:sanity.imagePaletteSwatch,background:#04447c,foreground:#fff,population:14.26,title:#fff},lightMuted:{_type:sanity.imagePaletteSwatch,background:#86aac5,foreground:#000,population:0.4,title:#fff},lightVibrant:{_type:sanity.imagePaletteSwatch,background:#cf9896,foreground:#000,population:2.43,title:#fff},muted:{_type:sanity.imagePaletteSwatch,background:#5c81ad,foreground:#fff,population:0.37,title:#fff},vibrant:{_type:sanity.imagePaletteSwatch,background:#145494,foreground:#fff,population:0.01,title:#fff}}},mimeType:image/png,originalFilename:Screenshot 2025-07-25 at 12.32.01 PM.png,path:images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png,sha1hash:c3816195de60a1c9a3186cb359096b06bf6cedac,size:613837,uploadId:8nO8XuNksXDkU8MTGJgCFRxXFO2LqUyT,url:https://cdn.sanity.io/images/0vv8moc6/targetedonc/c3816195de60a1c9a3186cb359096b06bf6cedac-944x532.png}},title:Zanubrutinib in TN CLL: Expert Insights on Latest Data From SEQUOIA Arm C,url:zanubrutinib-in-tn-cll-expert-insights-on-latest-data-from-sequoia-arm-c,link:/view/undefined},popUpVideos:,tiData:{brandNames:Onclive,CenterForBiosimilars,DiagnosticImaging,TargetedOncology,TI_id:69fe04f0-7b5b-4ae3-b2a0-0b9d967852e0,title:PERs Satellite Symposia at MHS,releaseDate:2024-05-24T04:00:00,courseEndDate:2025-08-03T03:59:59,description:August 1-2, 2025,slug:pers-satellite-symposia-at-mhs,thumbnail:https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/anp0ybypdb9j-MSHGenericTICatalog750x361.png,contentTypeLabel:In-Person Event,activity-type:In Person,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:null,dataType:per},{brandNames:TargetedOncology,TI_id:717afa3c-cc22-469d-8958-8b1e51139cd5,title:24th Annual International Congress on the Future of Breast Cancer® East,releaseDate:2025-07-22T04:00:00,courseEndDate:2025-08-26T03:59:59,description:Joyce O’Shaughnessy, MD,slug:24th-annual-international-congress-on-the-future-of-breast-cancer-east,thumbnail:https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/7gyyfqzcd5vy-IBC25EASTRAPIDWebcardV2_TICatalog750x361.png,contentTypeLabel:Video,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:\u003e3,creditCertificate:16.0,dataType:per},{brandNames:TargetedOncology,ManagedHealthcareExec,TI_id:a69f634c-311e-44a0-bc32-04eb71c93182,title:Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management,releaseDate:2024-08-28T04:00:00,courseEndDate:2025-08-29T03:59:59,description:Jeneth Aquino, DNP, FNP-BC; Beth Sandy, MSN, CRNP, FAPO; Allison M. Walker, ACNP, MSN, MSW, BS,slug:differentiating-adverse-events-for-antibody-drug-conjugates-across-solid-tumor-management-cuq0,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ldmdft6xfk42-SONO24_InlineSession_ADC_Archive_TICatalog750x3611.png,contentTypeLabel:Video,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:1.0,dataType:per},{brandNames:TargetedOncology,Onclive,CenterForBiosimilars,TI_id:79ac8174-ee16-4b90-8078-6c98d31d0102,title:  Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West,releaseDate:2024-09-30T04:00:00,courseEndDate:2025-10-01T03:59:59,description:Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Heather McArthur, MD, MPH; Hope S. Rugo, MD, FASCO\n,slug:community-practice-connections-23rd-annual-international-congress-on-the-future-of-breast-cancer-west,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qau5c908qo6p-750x3612x31.png,contentTypeLabel:Multimedia,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:2.25,dataType:per},{brandNames:TargetedOncology,TI_id:78025182-7e25-4579-b936-fdcaec198005,title:23rd Annual School of Breast Oncology,releaseDate:2024-07-10T04:00:00,courseEndDate:2025-11-09T04:59:59,description:November 6-8, 2025,slug:school-of-breast-oncology,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/yz3v1oafy7yp-SOBO25_WebBanners_TICatalog750x361.png,contentTypeLabel:In-Person Event,activity-type:In Person,creditType:CME,creditAmount:\u003e3,creditCertificate:null,dataType:per},{brandNames:TargetedOncology,TI_id:3a3b9700-f4f7-4f21-90d1-99e6e8a237bc,title:Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments,releaseDate:2024-11-27T05:00:00,courseEndDate:2025-11-28T04:59:59,description:Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP,slug:community-practice-connections-navigating-early-stage-hrher2-breast-cancer-clinical-developments-and-innovative-treatments,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/j71l23fiym7b-TICatalog750x3612x1811.png,contentTypeLabel:Multimedia,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:1.25,dataType:per},{brandNames:TargetedOncology,TI_id:dda2bdf3-c168-49c4-a559-1d9aa99b3840,title:Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer,releaseDate:2024-12-20T05:00:00,courseEndDate:2025-12-21T04:59:59,description:Virginia Kaklamani, MD, DSc; William J Gradishar, MD, FASCO, FACP,slug:community-practice-connections-community-oncologists-role-in-selecting-optimal-oral-serd-treatment-for-hrher2-breast-cancer,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/4ph3yo50ru8x-CoC_SERDS_CPCWebBanners_TICatalog750x3611.png,contentTypeLabel:Multimedia,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:1.0,dataType:per},{brandNames:TargetedOncology,Onclive,CenterForBiosimilars,TI_id:6f5d4e7f-8e90-472a-bf29-5e791b917e33,title:Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care,releaseDate:2024-12-23T05:00:00,courseEndDate:2025-12-24T04:59:59,description:Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH,slug:community-practice-connections-case-discussions-in-tnbc-navigating-the-latest-advances-and-impact-of-disparities-in-care,thumbnail:https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/y8ph9goqn3tw-TICatalog750x3612x322.png,contentTypeLabel:Multimedia,activity-type:Online Activity,creditType:CME, NCPD,creditAmount:1 to 3,creditCertificate:1.0,dataType:per}}},__N_SSG:true},page:/,query:{},buildId:zQw7jHyvd9hhvqSVfZfeG,isFallback:false,gsp:true,appGip:true,scriptLoader:}/script>/body>/html>

Subdomains

Date	Domain	IP
image.email.targetedonc.com	2024-12-11	23.44.175.158
www.targetedonc.com	2025-08-04	76.76.21.98

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > www.targetedonc.com

Is this malicious?

DNS Resolutions

Port 443

Subdomains